<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03766581</url>
  </required_header>
  <id_info>
    <org_study_id>CV010-031</org_study_id>
    <nct_id>NCT03766581</nct_id>
  </id_info>
  <brief_title>A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel</brief_title>
  <acronym>AXIOMATIC-SSP</acronym>
  <official_title>A Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of BMS-986177, an Oral Factor XIa Inhibitor, for the Prevention of New Ischemic Stroke or New Covert Brain Infarction in Patients Receiving Aspirin and Clopidogrel Following Acute Ischemic Stroke or Transient Ischemic Attack (TIA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to determine whether the addition of an oral Factor XIa&#xD;
      Inhibitor to Aspirin and Clopidogrel is more effective than standard therapy in secondary&#xD;
      stroke prevention.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 27, 2019</start_date>
  <completion_date type="Actual">March 31, 2022</completion_date>
  <primary_completion_date type="Actual">March 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Participants With Model Based Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90</measure>
    <time_frame>From randomization to up to 90 days after randomization</time_frame>
    <description>Model based assessment estimate for composite event is a customized statistical analysis called MCP-MOD (Multiple Comparison Procedures, MODel) estimation, which is used to check for dose-response relationship. 95% confidence interval (CI) for composite event based on bootstrap (10000 samples).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Major Bleeding According to BARC Type 3 and 5</measure>
    <time_frame>From first dose to up to 107 days after first dose</time_frame>
    <description>Percent of participants with major bleeding based on the Bleeding Academic Research Consortium (BARC) Types 3 and 5 definitions. BARC bleeding types:&#xD;
3a = Overt bleeding plus hemoglobin drop of 3 to &lt; 5 g/dL transfusion with overt bleeding 3b = Overt bleeding plus hemoglobin drop ≥5 g/dL; cardiac tamponade; bleeding requiring surgical intervention for control; bleeding requiring IV vasoactive agents 3c = Intracranial hemorrhage, 5a = Probable fatal bleeding 5b = Definite fatal bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Bleeding Based on BARC Types 1-5</measure>
    <time_frame>From first dose to up to 107 days after first dose</time_frame>
    <description>Number of participants with bleeding based on Bleeding Academic Research Consortium (BARC) Type 1 to 5. BARC bleeding types: 0=No bleeding. 1=Not actionable bleeding. 2=Overt, actionable sign of hemorrhage requiring nonsurgical, medical intervention by a health-care professional, leading to hospitalization or increased level of care, or prompting evaluation. 3a=Overt bleeding plus hemoglobin drop of 3 to &lt; 5 g/dL. 3b=Overt bleeding plus hemoglobin drop ≥5 g/dL; cardiac tamponade; bleeding requiring surgical intervention; bleeding requiring IV vasoactive agents. 3c=Intracranial hemorrhage; intraocular bleed compromising vision. 4=CABG-related bleeding, perioperative intracranial bleeding within 48 hours, reoperation after closure of sternotomy to control bleeding, transfusion of ≥5 U whole blood or packed red blood cells within a 48-hour period, chest tube output more than or equal to 2L within a 24-hour period. 5a=Probable fatal bleeding. 5b=Definite fatal bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Bleeding Based on ISTH-Defined Criteria</measure>
    <time_frame>From first dose to up to 107 days after first dose</time_frame>
    <description>Number of participants with bleeding based on International Society on Thrombosis and Hemostasis (ISTH). ISTH Bleeding Types: 1) Fatal bleeding and/or 2) Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome and/or 3) Bleeding causing a fall in hemoglobin level of ≥2 g/dL, or leading to transfusion of ≥2 units of whole blood or red cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Bleeding Based on PLATO-Defined Criteria</measure>
    <time_frame>From first dose to up to 107 days after first dose</time_frame>
    <description>Number of participants with bleeding based on Platelet Inhibition and Patient Outcomes (PLATO) defined criteria. PLATO bleeding definitions:&#xD;
Major Life-threatening: Fatal, Intracranial, Intrapericardial with cardiac tamponade, Resulting in hypovolemic shock or severe hypotension that requires pressors or surgery, Clinically overt or apparent bleeding associated with decrease in hemoglobin &gt;5 g/dL, Requiring transfusion of ≥4 U whole blood or packed red blood cells (PRBCs)&#xD;
Other Major: Significantly disabling (eg, intraocular with permanent vision loss), Associated drop in hemoglobin of 3 to 5 g/dL, Requiring transfusion of 2 to 3 U whole blood or PRBCs&#xD;
Any Major: Any one of the above criteria&#xD;
Minor: Bleeding that does not meet criteria for PLATO Major bleeding, and requiring medical intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Descriptive Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90</measure>
    <time_frame>From randomization to up to 90 days after randomization</time_frame>
    <description>Descriptive Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of Percent of Participants With New Ischemic Stroke, MI and All Cause Death</measure>
    <time_frame>From randomization to up to 90 days after randomization</time_frame>
    <description>Composite of percent of participants of new ischemic stroke, (Myocardial Infarction) MI and all cause death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institutes of Health Stroke Scale (NIHSS)</measure>
    <time_frame>At baseline, on Days 21 and 90, and at the time of a new stroke event</time_frame>
    <description>The NIHSS is an 11-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. The score for each ability is a number between 0 and 4, 0 being normal functioning and 4 being completely impaired. The patient's NIHSS score is calculated by adding the number for each element of the scale; 42 is the highest score possible. In the NIHSS, the higher the score, the more impaired a stroke participant is.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale (mRS)</measure>
    <time_frame>At baseline, on Days 21 and 90, and at the time of a new stroke event</time_frame>
    <description>The Modified Rankin Score (mRS) is a 6-point disability scale with possible scores ranging from 0 to 6.&#xD;
0 = No symptoms at all&#xD;
= No significant disability despite symptoms; able to carry out all usual duties and activities&#xD;
= Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance&#xD;
= Moderate disability; requiring some help, but able to walk without assistance&#xD;
= Moderately severe disability; unable to walk and attend to bodily needs without assistance&#xD;
= Severe disability; bedridden, incontinent and requiring constant nursing care and attention&#xD;
= Dead</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognitive Assessment (MoCA)</measure>
    <time_frame>At baseline, on Days 21 and 90, and at the time of a new stroke event</time_frame>
    <description>The Montreal Cognitive Assessment (MoCA) is a survey with a summed score. MoCA score ranges between a lowest score of 0 to a highest score of 30. A score of:&#xD;
≥26 points: indicates normal cognitive function&#xD;
18-25 points: Mild cognitive impairment&#xD;
10-17 points: Moderate cognitive impairment&#xD;
fewer than 10 points: Severe cognitive impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digit Symbol Substitution Test (DSST)</measure>
    <time_frame>At baseline, on Days 21 and 90, and at the time of a new stroke event</time_frame>
    <description>The Descriptive Summary of the Digit Symbol Substitution Test (DSST) is a scale item, with a lowest score of 0 and highest total score of 135. Higher score indicates better cognitive functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>From first dose to 2 days after last dose of study therapy (up to approximately 107 days)</time_frame>
    <description>AE: include all non-serious adverse events with onset on or after first dose date and within 2 days after the last dose of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Vital Sign Abnormalities</measure>
    <time_frame>From first dose to up to 90 days after first dose</time_frame>
    <description>Number of participants with clinically significant vital sign abnormalities. Vital signs included heart rate and diastolic and systolic blood pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Physical Examination Abnormalities</measure>
    <time_frame>From first dose to up to 90 days after first dose</time_frame>
    <description>Number of participants with clinically significant physical examination abnormalities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities</measure>
    <time_frame>From first dose to up to 90 days after first dose</time_frame>
    <description>Number of participants with clinically significant ECG abnormalities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Laboratory Abnormalities - Liver</measure>
    <time_frame>From first dose to up to approximately 38 months</time_frame>
    <description>The number of treated participants who experienced a laboratory abnormality of the liver during the course of the study.&#xD;
Aspartate aminotransferase (AST) Alanine aminotransferase (ALT) Upper Limit of Normal (ULN) Results reported in International System of Units (SI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in aPTT Activity</measure>
    <time_frame>Baseline and day 90</time_frame>
    <description>Percent change from baseline in activated partial thromboplastin time (aPTT) activity via exposure response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Factor XI Clotting Activity</measure>
    <time_frame>Baseline and day 90</time_frame>
    <description>Percent change from baseline in factor XI clotting activity via exposure response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter - Estimated Clearance (CL)</measure>
    <time_frame>From first dose to up to 90 days after first dose</time_frame>
    <description>Pharmacokinetic Parameter - Estimated Clearance (CL). CL is derived from plasma concentration versus time data. PK parameters were generated using a Population Pharmacokinetics (PPK) model. Summary statistics for these individual predicted PK parameters and exposures were stratified by dose. The PPK model analysis was based on combined PK data collected on days 1, 21, and 90.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter - Volume of the Central Compartment (VC)</measure>
    <time_frame>From first dose to up to 90 days after first dose</time_frame>
    <description>Pharmacokinetic Parameter - Volume of the Central Compartment (VC). VC is derived from plasma concentration versus time data. PK parameters were generated using a Population Pharmacokinetics (PPK) model. Summary statistics for these individual predicted PK parameters and exposures were stratified by dose. The PPK model analysis was based on combined PK data collected on days 1, 21, and 90.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Incident Infarcts (New DWI+ or DWI- Lesions) by Participant on Day 90 MRI</measure>
    <time_frame>At day 90</time_frame>
    <description>Total volume of diffusion-weighted imaging (DWI) magnetic resonance imaging (MRI) infarcts on the DWI Sequence on day 90 MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Incident Infarcts (New DWI+ or DWI- Lesions) by Participant on Day 90 MRI</measure>
    <time_frame>At day 90</time_frame>
    <description>Number of diffusion-weighted imaging (DWI) magnetic resonance imaging (MRI) infarcts on the DWI Sequence on day 90 MRI.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percent of Participants With Ischemic Stroke Events</measure>
    <time_frame>From randomization to up to 90 days after randomization</time_frame>
    <description>Secondary analysis of symptomatic ischemic stroke events. Clinical events are included up to day 90. Wald 95% CI within group. Undetermined stroke is included.</description>
  </other_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">2366</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <condition>Transient Ischemic Attack (TIA)</condition>
  <arm_group>
    <arm_group_label>BMS-986177 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Specified Dose on Specified Days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 1: BMS-986177 + Aspirin + Clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Specified Dose on Specified Days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2: BMS-986177 + Aspirin + Clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Specified Dose on Specified Days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3: BMS-986177 + Aspirin + Clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Specified Dose on Specified Days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 4: BMS-986177 + Aspirin + Clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Specified Dose on Specified Days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 5: BMS-986177 + Aspirin + Clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Specified Dose on Specified Days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 6: BMS-986177 + Aspirin + Clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Specified Dose on Specified Days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 7: BMS-986177 + Aspirin + Clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Specified Dose on Specified Days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986177</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Dose 1: BMS-986177 + Aspirin + Clopidogrel</arm_group_label>
    <arm_group_label>Dose 2: BMS-986177 + Aspirin + Clopidogrel</arm_group_label>
    <arm_group_label>Dose 3: BMS-986177 + Aspirin + Clopidogrel</arm_group_label>
    <arm_group_label>Dose 4: BMS-986177 + Aspirin + Clopidogrel</arm_group_label>
    <arm_group_label>Dose 5: BMS-986177 + Aspirin + Clopidogrel</arm_group_label>
    <arm_group_label>Dose 6: BMS-986177 + Aspirin + Clopidogrel</arm_group_label>
    <arm_group_label>Dose 7: BMS-986177 + Aspirin + Clopidogrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral Administration</description>
    <arm_group_label>BMS-986177 Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>BMS-986177 Placebo</arm_group_label>
    <arm_group_label>Dose 1: BMS-986177 + Aspirin + Clopidogrel</arm_group_label>
    <arm_group_label>Dose 2: BMS-986177 + Aspirin + Clopidogrel</arm_group_label>
    <arm_group_label>Dose 3: BMS-986177 + Aspirin + Clopidogrel</arm_group_label>
    <arm_group_label>Dose 4: BMS-986177 + Aspirin + Clopidogrel</arm_group_label>
    <arm_group_label>Dose 5: BMS-986177 + Aspirin + Clopidogrel</arm_group_label>
    <arm_group_label>Dose 6: BMS-986177 + Aspirin + Clopidogrel</arm_group_label>
    <arm_group_label>Dose 7: BMS-986177 + Aspirin + Clopidogrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>BMS-986177 Placebo</arm_group_label>
    <arm_group_label>Dose 1: BMS-986177 + Aspirin + Clopidogrel</arm_group_label>
    <arm_group_label>Dose 2: BMS-986177 + Aspirin + Clopidogrel</arm_group_label>
    <arm_group_label>Dose 3: BMS-986177 + Aspirin + Clopidogrel</arm_group_label>
    <arm_group_label>Dose 4: BMS-986177 + Aspirin + Clopidogrel</arm_group_label>
    <arm_group_label>Dose 5: BMS-986177 + Aspirin + Clopidogrel</arm_group_label>
    <arm_group_label>Dose 6: BMS-986177 + Aspirin + Clopidogrel</arm_group_label>
    <arm_group_label>Dose 7: BMS-986177 + Aspirin + Clopidogrel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and Female ≥40 years of age&#xD;
&#xD;
          -  Acute Ischemic Stroke or Transient Ischemic Attack&#xD;
&#xD;
          -  Intracranial or Extracranial Atherosclerotic Plaque proximal to the affected brain&#xD;
             area&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Predicted inability to swallow study medication&#xD;
&#xD;
          -  Any condition that, in the opinion of the Investigator, contraindicates anticoagulant&#xD;
             therapy or would have an unacceptable risk of bleeding&#xD;
&#xD;
          -  Use of thrombolytic therapy or mechanical thrombectomy for treatment of index stroke&#xD;
&#xD;
        Other protocol defined inclusion/exclusion criteria could apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution - 0029</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0007</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0006</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Los Angeles Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0231</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0376</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0004</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0042</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0340</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0075</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0013</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0024</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0015</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0428</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0293</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois Hospital &amp; Health Sciences System</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0430</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0382</name>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <zip>61114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0346</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0047</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0420</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0236</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0434</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0375</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0294</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0352</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Neurology Specialists PLLC</name>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <zip>59405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0276</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0039</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0354</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0125</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Butner</city>
        <state>North Carolina</state>
        <zip>27509-1626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0043</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0016</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0003</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0050</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0419</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0218</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0022</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0302</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103-6381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <zip>17011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0018</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16550-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0020</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0019</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0041</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0009</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0008</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Consultants of Dallas, PA</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-88520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical center of El Paso</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0040</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0093</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0187</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0100</name>
      <address>
        <city>Adrogué</city>
        <state>Buenos Aires</state>
        <zip>B1846DSK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0063</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1199ABB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0076</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1428AQK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0067</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1180AAX</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0237</name>
      <address>
        <city>Lomas de Zamora</city>
        <state>Buenos Aires</state>
        <zip>1832</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0435</name>
      <address>
        <city>Recoleta</city>
        <state>Buenos Aires</state>
        <zip>C1115AAB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1437</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0068</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1425DND</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Santa Fe</city>
        <zip>3000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0329</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0360</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0287</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0399</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0397</name>
      <address>
        <city>Launceston</city>
        <state>Tasmania</state>
        <zip>7250</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0358</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0281</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0315</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0184</name>
      <address>
        <city>Klagenfurt Am Woerthersee</city>
        <zip>9020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>St. Pölten</city>
        <zip>3100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0106</name>
      <address>
        <city>Vocklabruck</city>
        <zip>4840</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0273</name>
      <address>
        <city>Wien</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0122</name>
      <address>
        <city>Edegem</city>
        <state>Antwerpen</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0196</name>
      <address>
        <city>Brussel</city>
        <state>Brussels</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0192</name>
      <address>
        <city>Yvoir</city>
        <state>Namur</state>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Brasschaat</city>
        <zip>2930</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0284</name>
      <address>
        <city>Bruges</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0427</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0190</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0305</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0199</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0103</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0098</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0178</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0072</name>
      <address>
        <city>Fortaleza</city>
        <state>Ceara</state>
        <zip>60175-295</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0275</name>
      <address>
        <city>Uberaba</city>
        <state>Minas Gerais</state>
        <zip>38025-260</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0314</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>80060-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0200</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0219</name>
      <address>
        <city>Joinville</city>
        <state>Santa Catarina</state>
        <zip>89202 165</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0245</name>
      <address>
        <city>Botucatu</city>
        <state>SAO Paulo</state>
        <zip>18618-686</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0065</name>
      <address>
        <city>Campinas</city>
        <state>SAO Paulo</state>
        <zip>13083-970</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ribeirao Preto</city>
        <state>SAO Paulo</state>
        <zip>14051-140</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0113</name>
      <address>
        <city>Santo Andre</city>
        <state>SAO Paulo</state>
        <zip>09030-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0234</name>
      <address>
        <city>São Paulo</city>
        <state>SAO Paulo</state>
        <zip>01221-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0248</name>
      <address>
        <city>São Paulo</city>
        <state>SAO Paulo</state>
        <zip>04024-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0057</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0061</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2G3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0059</name>
      <address>
        <city>Lethbridge</city>
        <state>Alberta</state>
        <zip>T1J 0N9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0369</name>
      <address>
        <city>New Westminster</city>
        <state>British Columbia</state>
        <zip>V3L 0E3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0121</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0054</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0227</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0124</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0326</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 5H6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0155</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0066</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0064</name>
      <address>
        <city>Quebec</city>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0172</name>
      <address>
        <city>Viña del Mar</city>
        <state>Valparaiso</state>
        <zip>2520612</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Los Angeles</city>
        <zip>441055</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0131</name>
      <address>
        <city>Valdivia</city>
        <zip>5090145</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0167</name>
      <address>
        <city>Viña del Mar</city>
        <zip>0</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100070</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <zip>570311</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Daqing</city>
        <state>Heilongjiang</state>
        <zip>163001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nantong</city>
        <state>Jiangsu</state>
        <zip>226001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Yangzhou</city>
        <state>Jiangsu</state>
        <zip>225001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>YanTai</city>
        <state>Shandong</state>
        <zip>264000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0401</name>
      <address>
        <city>Olomouc</city>
        <state>Olomoucký Kraj</state>
        <zip>779 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0348</name>
      <address>
        <city>Jihlava</city>
        <state>Vysocina</state>
        <zip>586 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ceske Budejovice</city>
        <zip>370 87</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0023</name>
      <address>
        <city>Ostrava</city>
        <zip>703 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0339</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0117</name>
      <address>
        <city>Herlev</city>
        <state>Capital</state>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0217</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0127</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0142</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0110</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0111</name>
      <address>
        <city>Helsinki</city>
        <zip>290</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0341</name>
      <address>
        <city>Lappeenranta</city>
        <zip>53130</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0143</name>
      <address>
        <city>Turku</city>
        <zip>FI-20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0442</name>
      <address>
        <city>Montpellier</city>
        <state>Hérault</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0048</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0051</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bourg-en-Bresse</city>
        <zip>01012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0165</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0174</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Limoges Cedex</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0168</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0297</name>
      <address>
        <city>Nancy</city>
        <zip>54035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0205</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0049</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0126</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0028</name>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0107</name>
      <address>
        <city>Rouen Cedex</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0355</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0391</name>
      <address>
        <city>Sindelfingen</city>
        <state>Baden-Württemberg</state>
        <zip>71065</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0045</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0285</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>65929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0090</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0258</name>
      <address>
        <city>Lübeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0011</name>
      <address>
        <city>Altenburg</city>
        <zip>04600</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0032</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bielefeld</city>
        <zip>33617</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0250</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0380</name>
      <address>
        <city>Bremen</city>
        <zip>28755</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0144</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0097</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0053</name>
      <address>
        <city>Essen</city>
        <zip>45131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0291</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60528</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0254</name>
      <address>
        <city>Gießen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0056</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0044</name>
      <address>
        <city>Hamburg</city>
        <zip>22043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0034</name>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hannover</city>
        <zip>D30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0055</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0036</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0256</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0378</name>
      <address>
        <city>Osnabruck</city>
        <zip>49076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0367</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0387</name>
      <address>
        <city>Sande</city>
        <zip>26452</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Siegen</city>
        <zip>57076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0241</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0438</name>
      <address>
        <city>Athina</city>
        <state>Attiki</state>
        <zip>115 21</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0357</name>
      <address>
        <city>Larissa</city>
        <state>Larisa</state>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0370</name>
      <address>
        <city>Athens</city>
        <zip>106 76</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0436</name>
      <address>
        <city>Athens</city>
        <zip>11525</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0440</name>
      <address>
        <city>Athens</city>
        <zip>11526</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0373</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0209</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0283</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0351</name>
      <address>
        <city>Athens</city>
        <zip>12461</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0407</name>
      <address>
        <city>Crete</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ioannina</city>
        <zip>45445</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0161</name>
      <address>
        <city>Larissa</city>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0441</name>
      <address>
        <city>Larissa</city>
        <zip>41221</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0333</name>
      <address>
        <city>Loanniana</city>
        <zip>45500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0365</name>
      <address>
        <city>Loanniana</city>
        <zip>45500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0439</name>
      <address>
        <city>Neo Faliro</city>
        <zip>18547</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0371</name>
      <address>
        <city>Patras</city>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0208</name>
      <address>
        <city>Pireaus</city>
        <zip>18536</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0405</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54621</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0269</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0389</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0444</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0210</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56403</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0445</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0070</name>
      <address>
        <city>Miskolc</city>
        <state>BZ</state>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0134</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0077</name>
      <address>
        <city>Budapest</city>
        <zip>1106</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0119</name>
      <address>
        <city>Budapest</city>
        <zip>1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0136</name>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0154</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0079</name>
      <address>
        <city>Gyor</city>
        <zip>9024</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0175</name>
      <address>
        <city>Kistarcsa</city>
        <zip>02143</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0437</name>
      <address>
        <city>Kisvárda</city>
        <zip>4600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0220</name>
      <address>
        <city>Nyíregyháza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0138</name>
      <address>
        <city>Pecs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0133</name>
      <address>
        <city>Szeged</city>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0137</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Beer-Sheva</city>
        <zip>85025</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0139</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0349</name>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0193</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0078</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0308</name>
      <address>
        <city>Nahariya</city>
        <zip>22100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0247</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0204</name>
      <address>
        <city>Ramat-Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0086</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0359</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0084</name>
      <address>
        <city>Pavia</city>
        <state>Lombardia</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0151</name>
      <address>
        <city>Ancona</city>
        <state>Marche</state>
        <zip>60020</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0149</name>
      <address>
        <city>Negrar</city>
        <state>Veneto</state>
        <zip>37024</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0156</name>
      <address>
        <city>Bologna</city>
        <zip>40133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0290</name>
      <address>
        <city>Cagliari</city>
        <zip>09134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0095</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0104</name>
      <address>
        <city>Modena</city>
        <zip>1355-41126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0085</name>
      <address>
        <city>Perugia</city>
        <zip>06012</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0114</name>
      <address>
        <city>Perugia</city>
        <zip>06129</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0108</name>
      <address>
        <city>Roma</city>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0129</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0083</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0123</name>
      <address>
        <city>Vibo Valentia</city>
        <zip>89900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0335</name>
      <address>
        <city>Kasugai</city>
        <state>Aichi</state>
        <zip>487-0016</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0274</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <zip>4600001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0331</name>
      <address>
        <city>Toyoake Shi</city>
        <state>Aichi</state>
        <zip>4701192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0325</name>
      <address>
        <city>Toyohashi-shi</city>
        <state>Aichi</state>
        <zip>440-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0317</name>
      <address>
        <city>Toyota-shi</city>
        <state>Aichi</state>
        <zip>471-8513</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0336</name>
      <address>
        <city>Sakura-shi</city>
        <state>Chiba</state>
        <zip>285-8741</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0320</name>
      <address>
        <city>Chikushino-shi</city>
        <state>Fukuoka</state>
        <zip>818-8516</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0259</name>
      <address>
        <city>Kasuga-shi</city>
        <state>Fukuoka</state>
        <zip>816-0864</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0229</name>
      <address>
        <city>Kitakyushu-shi</city>
        <state>Fukuoka</state>
        <zip>802-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0270</name>
      <address>
        <city>Kitakyushu-shi</city>
        <state>Fukuoka</state>
        <zip>8058508</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0311</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <zip>800-0296</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0230</name>
      <address>
        <city>Koga-shi</city>
        <state>Fukuoka</state>
        <zip>811-3113</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0324</name>
      <address>
        <city>Kurume City</city>
        <state>Fukuoka</state>
        <zip>830-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0257</name>
      <address>
        <city>Aizuwakamatsu-shi</city>
        <state>Fukushima</state>
        <zip>9658585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0309</name>
      <address>
        <city>Takayama-shi</city>
        <state>Gifu</state>
        <zip>506-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0211</name>
      <address>
        <city>Isesaki-shi</city>
        <state>Gunma</state>
        <zip>372-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0337</name>
      <address>
        <city>Aki-gun</city>
        <state>Hiroshima</state>
        <zip>735-8585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0240</name>
      <address>
        <city>Higashihiroshima-shi</city>
        <state>Hiroshima</state>
        <zip>739-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0328</name>
      <address>
        <city>Hiroshima-shi</city>
        <state>Hiroshima</state>
        <zip>731-0293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0226</name>
      <address>
        <city>Kobe-City</city>
        <state>Hyogo</state>
        <zip>650-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0323</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <zip>920-8650</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0446</name>
      <address>
        <city>Komatsu</city>
        <state>Ishikawa</state>
        <zip>923-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0299</name>
      <address>
        <city>Kagoshima-shi</city>
        <state>Kagoshima</state>
        <zip>890-8760</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0228</name>
      <address>
        <city>Kawasaki-city</city>
        <state>Kanagawa</state>
        <zip>216-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0310</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <zip>211-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0296</name>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi</state>
        <zip>982-8523</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0278</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>9838520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0261</name>
      <address>
        <city>Nagasaki-shi</city>
        <state>Nagasaki</state>
        <zip>8528501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0272</name>
      <address>
        <city>Izumisano-shi</city>
        <state>Osaka</state>
        <zip>5988577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kishiwada</city>
        <state>Osaka</state>
        <zip>596-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0279</name>
      <address>
        <city>Matsubara</city>
        <state>Osaka</state>
        <zip>580-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0322</name>
      <address>
        <city>Sakai-shi</city>
        <state>Osaka</state>
        <zip>590-0064</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0244</name>
      <address>
        <city>Suita-shi</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0251</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>5648565</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0263</name>
      <address>
        <city>Hidaka</city>
        <state>Saitama</state>
        <zip>858+6</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0334</name>
      <address>
        <city>Shimotsuke-shi</city>
        <state>Tochigi</state>
        <zip>3290498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0232</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8603</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0343</name>
      <address>
        <city>Hachioji</city>
        <state>Tokyo</state>
        <zip>192-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0255</name>
      <address>
        <city>Meguro-ku</city>
        <state>Tokyo</state>
        <zip>152-8902</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0338</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>1058471</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0342</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>108-0073</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0295</name>
      <address>
        <city>Mitaka-shi</city>
        <state>Tokyo</state>
        <zip>181-8611</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0298</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>141-8625</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0316</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0318</name>
      <address>
        <city>Tachikawa-shi</city>
        <state>Tokyo</state>
        <zip>1900014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0319</name>
      <address>
        <city>Shimonoseki-Shi</city>
        <state>Yamaguchi</state>
        <zip>752-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0271</name>
      <address>
        <city>Fukuoka</city>
        <zip>810-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0243</name>
      <address>
        <city>Fukuoka</city>
        <zip>810-8563</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0312</name>
      <address>
        <city>Kyoto</city>
        <zip>6008558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0327</name>
      <address>
        <city>Osaka</city>
        <zip>533-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0239</name>
      <address>
        <city>Osaka</city>
        <zip>540-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0313</name>
      <address>
        <city>Osaka</city>
        <zip>558-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0301</name>
      <address>
        <city>Saga</city>
        <zip>849-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0094</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggido</state>
        <zip>10380</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0088</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0081</name>
      <address>
        <city>Anyang</city>
        <zip>431-070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0109</name>
      <address>
        <city>Busan</city>
        <zip>49201</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0166</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0179</name>
      <address>
        <city>Daegu</city>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0102</name>
      <address>
        <city>Daegu</city>
        <zip>42415</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Daegu</city>
        <zip>700-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0105</name>
      <address>
        <city>Gwangju</city>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0101</name>
      <address>
        <city>Incheon</city>
        <zip>22332</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0153</name>
      <address>
        <city>Seongnam-si</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0087</name>
      <address>
        <city>Seoul</city>
        <zip>01830</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0185</name>
      <address>
        <city>Seoul</city>
        <zip>02447</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0071</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0080</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0120</name>
      <address>
        <city>Seoul</city>
        <zip>04763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0145</name>
      <address>
        <city>Seoul</city>
        <zip>06273</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0152</name>
      <address>
        <city>Seoul</city>
        <zip>07061</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0112</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0091</name>
      <address>
        <city>Seoul</city>
        <zip>130-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ciudad de Mexico</city>
        <state>Distrito Federal</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0398</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>14269</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0396</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44670</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0404</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo LEON</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0394</name>
      <address>
        <city>Culiacan</city>
        <state>Sinaloa</state>
        <zip>80020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0366</name>
      <address>
        <city>Durango</city>
        <zip>34217</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0368</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0383</name>
      <address>
        <city>Grålum</city>
        <zip>1714</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kristiansand</city>
        <zip>4604</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0130</name>
      <address>
        <city>Lørenskog</city>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0408</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0330</name>
      <address>
        <city>Stavanger</city>
        <zip>4068</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0265</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>04-141</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0350</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-094</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0216</name>
      <address>
        <city>Chelm</city>
        <zip>22-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0206</name>
      <address>
        <city>Gdansk</city>
        <zip>80-803</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0181</name>
      <address>
        <city>Grodzisk Mazowieciki</city>
        <zip>05-825</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0253</name>
      <address>
        <city>Katowice</city>
        <zip>40-635</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Konskie</city>
        <zip>26-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0197</name>
      <address>
        <city>Lodz</city>
        <zip>93-113</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0198</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-561</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0215</name>
      <address>
        <city>Sandomierz</city>
        <zip>27-600</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0183</name>
      <address>
        <city>Skarzysko-Kamienna</city>
        <zip>26-110</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0225</name>
      <address>
        <city>Walcz</city>
        <zip>78-600</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0214</name>
      <address>
        <city>Warszawa</city>
        <zip>02-957</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0212</name>
      <address>
        <city>Wejherowo</city>
        <zip>84-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0277</name>
      <address>
        <city>Barnaul</city>
        <zip>656038</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0260</name>
      <address>
        <city>Kemerovo</city>
        <zip>650002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0306</name>
      <address>
        <city>Moscow</city>
        <zip>117593</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Moscow</city>
        <zip>125367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0268</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0202</name>
      <address>
        <city>Smolensk</city>
        <zip>214018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0356</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150030</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0159</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0163</name>
      <address>
        <city>Sant Joan Despi</city>
        <state>Barcelona</state>
        <zip>08970</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0372</name>
      <address>
        <city>León</city>
        <state>Castilla Y León</state>
        <zip>24071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0141</name>
      <address>
        <city>A Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0026</name>
      <address>
        <city>Albacete</city>
        <zip>02006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0052</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0012</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0010</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0027</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0385</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0426</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0176</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0249</name>
      <address>
        <city>Lleida</city>
        <zip>25008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0238</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0025</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0413</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0384</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0400</name>
      <address>
        <city>San Sebastian</city>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0425</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0158</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0177</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0164</name>
      <address>
        <city>Tarragona</city>
        <zip>43005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0150</name>
      <address>
        <city>Terrassa</city>
        <zip>08222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0147</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0014</name>
      <address>
        <city>Valladolid</city>
        <zip>47005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0418</name>
      <address>
        <city>Vigo</city>
        <zip>36312</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0128</name>
      <address>
        <city>Malmö</city>
        <state>Skane Lan</state>
        <zip>SE-205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0171</name>
      <address>
        <city>Göteborg</city>
        <zip>SE-43146</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0191</name>
      <address>
        <city>Hassleholm</city>
        <zip>28125</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0224</name>
      <address>
        <city>Umea</city>
        <zip>901 87</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0132</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-752 37</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0118</name>
      <address>
        <city>Basel</city>
        <state>Basel-Stadt (de)</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0115</name>
      <address>
        <city>Bern</city>
        <state>Bern (de)</state>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0162</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0203</name>
      <address>
        <city>Geneve</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0201</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Zurich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0222</name>
      <address>
        <city>Canterbury</city>
        <state>Kent</state>
        <zip>CT1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0140</name>
      <address>
        <city>Aberdeen</city>
        <zip>AB25 2ZD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ashford</city>
        <zip>TN24 0LZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0157</name>
      <address>
        <city>Bath</city>
        <zip>BA1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0089</name>
      <address>
        <city>Chester</city>
        <zip>CH2 1UL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0221</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0096</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0361</name>
      <address>
        <city>Lancashire</city>
        <zip>BL9 7TD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>London</city>
        <zip>SE5 9RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>London</city>
        <zip>W1T 7HA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0303</name>
      <address>
        <city>Luton</city>
        <zip>LU4 0DZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0431</name>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0414</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution - 0307</name>
      <address>
        <city>Staffordshire</city>
        <zip>ST4 6QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.BMSStudyConnect.com</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <verification_date>June 2023</verification_date>
  <study_first_submitted>November 13, 2018</study_first_submitted>
  <study_first_submitted_qc>December 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2018</study_first_posted>
  <results_first_submitted>March 31, 2023</results_first_submitted>
  <results_first_submitted_qc>June 8, 2023</results_first_submitted_qc>
  <results_first_posted type="Actual">June 12, 2023</results_first_posted>
  <last_update_submitted>June 8, 2023</last_update_submitted>
  <last_update_submitted_qc>June 8, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Ischemic Attack, Transient</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 9, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT03766581/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
        </group>
        <group group_id="P2">
          <title>Milvexian 25 mg QD</title>
          <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
        </group>
        <group group_id="P3">
          <title>Milvexian 25 mg BID</title>
          <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
        </group>
        <group group_id="P4">
          <title>Milvexian 50 mg BID</title>
          <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
        </group>
        <group group_id="P5">
          <title>Milvexian 100 mg BID</title>
          <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
        </group>
        <group group_id="P6">
          <title>Milvexian 200 mg BID</title>
          <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
        </group>
        <group group_id="P7">
          <title>Milvexian 50 mg QD</title>
          <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
        </group>
        <group group_id="P8">
          <title>Milvexian 100 mg QD</title>
          <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomization</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="691"/>
                <participants group_id="P2" count="328"/>
                <participants group_id="P3" count="318"/>
                <participants group_id="P4" count="328"/>
                <participants group_id="P5" count="310"/>
                <participants group_id="P6" count="351"/>
                <participants group_id="P7" count="22"/>
                <participants group_id="P8" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="682"/>
                <participants group_id="P2" count="324"/>
                <participants group_id="P3" count="313"/>
                <participants group_id="P4" count="325"/>
                <participants group_id="P5" count="306"/>
                <participants group_id="P6" count="345"/>
                <participants group_id="P7" count="22"/>
                <participants group_id="P8" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other reasons</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant no longer meets study criteria</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant request to discontinue study treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="682"/>
                <participants group_id="P2" count="325">1 participant was randomized to Milvexian 200 mg BID, but received Milvexian 25 mg QD.</participants>
                <participants group_id="P3" count="313"/>
                <participants group_id="P4" count="325"/>
                <participants group_id="P5" count="306"/>
                <participants group_id="P6" count="344">1 participant was randomized to Milvexian 200 mg BID, but received Milvexian 25 mg QD.</participants>
                <participants group_id="P7" count="22"/>
                <participants group_id="P8" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="529"/>
                <participants group_id="P2" count="260"/>
                <participants group_id="P3" count="242"/>
                <participants group_id="P4" count="251"/>
                <participants group_id="P5" count="230"/>
                <participants group_id="P6" count="240"/>
                <participants group_id="P7" count="15"/>
                <participants group_id="P8" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="153"/>
                <participants group_id="P2" count="65"/>
                <participants group_id="P3" count="71"/>
                <participants group_id="P4" count="74"/>
                <participants group_id="P5" count="76"/>
                <participants group_id="P6" count="104"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="47"/>
                <participants group_id="P4" count="46"/>
                <participants group_id="P5" count="50"/>
                <participants group_id="P6" count="77"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant request to discontinue treatment</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="15"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor/Non compliance</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant no longer meets study criteria</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
        </group>
        <group group_id="B2">
          <title>Milvexian 25 mg QD</title>
          <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
        </group>
        <group group_id="B3">
          <title>Milvexian 25 mg BID</title>
          <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
        </group>
        <group group_id="B4">
          <title>Milvexian 50 mg BID</title>
          <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
        </group>
        <group group_id="B5">
          <title>Milvexian 100 mg BID</title>
          <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
        </group>
        <group group_id="B6">
          <title>Milvexian 200 mg BID</title>
          <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
        </group>
        <group group_id="B7">
          <title>Milvexian 50 mg QD</title>
          <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
        </group>
        <group group_id="B8">
          <title>Milvexian 100 mg QD</title>
          <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="691"/>
            <count group_id="B2" value="328"/>
            <count group_id="B3" value="318"/>
            <count group_id="B4" value="328"/>
            <count group_id="B5" value="310"/>
            <count group_id="B6" value="351"/>
            <count group_id="B7" value="22"/>
            <count group_id="B8" value="18"/>
            <count group_id="B9" value="2366"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.1" spread="10.58"/>
                    <measurement group_id="B2" value="70.9" spread="10.66"/>
                    <measurement group_id="B3" value="70.1" spread="11.34"/>
                    <measurement group_id="B4" value="69.3" spread="10.69"/>
                    <measurement group_id="B5" value="69.7" spread="10.59"/>
                    <measurement group_id="B6" value="69.5" spread="11.11"/>
                    <measurement group_id="B7" value="65.7" spread="10.64"/>
                    <measurement group_id="B8" value="65.4" spread="11.65"/>
                    <measurement group_id="B9" value="69.6" spread="10.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="254"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="118"/>
                    <measurement group_id="B4" value="121"/>
                    <measurement group_id="B5" value="112"/>
                    <measurement group_id="B6" value="128"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="10"/>
                    <measurement group_id="B9" value="859"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="437"/>
                    <measurement group_id="B2" value="219"/>
                    <measurement group_id="B3" value="200"/>
                    <measurement group_id="B4" value="207"/>
                    <measurement group_id="B5" value="198"/>
                    <measurement group_id="B6" value="223"/>
                    <measurement group_id="B7" value="15"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="1507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="29"/>
                    <measurement group_id="B6" value="27"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="197"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="619"/>
                    <measurement group_id="B2" value="304"/>
                    <measurement group_id="B3" value="294"/>
                    <measurement group_id="B4" value="304"/>
                    <measurement group_id="B5" value="279"/>
                    <measurement group_id="B6" value="323"/>
                    <measurement group_id="B7" value="14"/>
                    <measurement group_id="B8" value="10"/>
                    <measurement group_id="B9" value="2147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Race</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="549"/>
                    <measurement group_id="B2" value="257"/>
                    <measurement group_id="B3" value="246"/>
                    <measurement group_id="B4" value="260"/>
                    <measurement group_id="B5" value="251"/>
                    <measurement group_id="B6" value="288"/>
                    <measurement group_id="B7" value="18"/>
                    <measurement group_id="B8" value="15"/>
                    <measurement group_id="B9" value="1884"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian Indian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chinese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japanese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="39"/>
                    <measurement group_id="B6" value="40"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants With Model Based Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90</title>
        <description>Model based assessment estimate for composite event is a customized statistical analysis called MCP-MOD (Multiple Comparison Procedures, MODel) estimation, which is used to check for dose-response relationship. 95% confidence interval (CI) for composite event based on bootstrap (10000 samples).</description>
        <time_frame>From randomization to up to 90 days after randomization</time_frame>
        <population>All randomized participants who experienced a new ischemic stroke by day 90, or an evaluable day 90 MRI regardless of when the MRI was collected. Dose -response model-based endpoint that was pre-specified for data to be collected only in the Placebo, 25 mg QD, and BID dose regimens.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Milvexian 25 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O3">
            <title>Milvexian 25 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O4">
            <title>Milvexian 50 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O5">
            <title>Milvexian 100 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O6">
            <title>Milvexian 200 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Model Based Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90</title>
          <description>Model based assessment estimate for composite event is a customized statistical analysis called MCP-MOD (Multiple Comparison Procedures, MODel) estimation, which is used to check for dose-response relationship. 95% confidence interval (CI) for composite event based on bootstrap (10000 samples).</description>
          <population>All randomized participants who experienced a new ischemic stroke by day 90, or an evaluable day 90 MRI regardless of when the MRI was collected. Dose -response model-based endpoint that was pre-specified for data to be collected only in the Placebo, 25 mg QD, and BID dose regimens.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="625"/>
                <count group_id="O2" value="308"/>
                <count group_id="O3" value="287"/>
                <count group_id="O4" value="306"/>
                <count group_id="O5" value="277"/>
                <count group_id="O6" value="317"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8" lower_limit="14.2" upper_limit="19.4"/>
                    <measurement group_id="O2" value="16.7" lower_limit="14.4" upper_limit="19.0"/>
                    <measurement group_id="O3" value="16.6" lower_limit="14.5" upper_limit="18.7"/>
                    <measurement group_id="O4" value="15.6" lower_limit="13.6" upper_limit="17.9"/>
                    <measurement group_id="O5" value="15.4" lower_limit="13.0" upper_limit="18.0"/>
                    <measurement group_id="O6" value="15.3" lower_limit="12.3" upper_limit="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Milvexian 25 mg QD over Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Relative Risk (RR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
            <estimate_desc>95% confidence interval (CI) for composite event based on bootstrap (10000 samples)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Milvexian 25 mg BID over Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Relative Risk (RR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
            <estimate_desc>95% confidence interval (CI) for composite event based on bootstrap (10000 samples)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Milvexian 50 mg BID over Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Relative Risk (RR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
            <estimate_desc>95% confidence interval (CI) for composite event based on bootstrap (10000 samples)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Milvexian 100 mg BID over Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Relative Risk (RR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
            <estimate_desc>95% confidence interval (CI) for composite event based on bootstrap (10000 samples)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Milvexian 200 mg BID over Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Relative Risk (RR)</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
            <estimate_desc>95% confidence interval (CI) for composite event based on bootstrap (10000 samples)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Major Bleeding According to BARC Type 3 and 5</title>
        <description>Percent of participants with major bleeding based on the Bleeding Academic Research Consortium (BARC) Types 3 and 5 definitions. BARC bleeding types:&#xD;
3a = Overt bleeding plus hemoglobin drop of 3 to &lt; 5 g/dL transfusion with overt bleeding 3b = Overt bleeding plus hemoglobin drop ≥5 g/dL; cardiac tamponade; bleeding requiring surgical intervention for control; bleeding requiring IV vasoactive agents 3c = Intracranial hemorrhage, 5a = Probable fatal bleeding 5b = Definite fatal bleeding</description>
        <time_frame>From first dose to up to 107 days after first dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Milvexian 25 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O3">
            <title>Milvexian 25 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O4">
            <title>Milvexian 50 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O5">
            <title>Milvexian 100 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O6">
            <title>Milvexian 200 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O7">
            <title>Milvexian 50 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O8">
            <title>Milvexian 100 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Major Bleeding According to BARC Type 3 and 5</title>
          <description>Percent of participants with major bleeding based on the Bleeding Academic Research Consortium (BARC) Types 3 and 5 definitions. BARC bleeding types:&#xD;
3a = Overt bleeding plus hemoglobin drop of 3 to &lt; 5 g/dL transfusion with overt bleeding 3b = Overt bleeding plus hemoglobin drop ≥5 g/dL; cardiac tamponade; bleeding requiring surgical intervention for control; bleeding requiring IV vasoactive agents 3c = Intracranial hemorrhage, 5a = Probable fatal bleeding 5b = Definite fatal bleeding</description>
          <population>All treated participants</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="682"/>
                <count group_id="O2" value="325"/>
                <count group_id="O3" value="313"/>
                <count group_id="O4" value="325"/>
                <count group_id="O5" value="306"/>
                <count group_id="O6" value="344"/>
                <count group_id="O7" value="22"/>
                <count group_id="O8" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.2" upper_limit="1.5"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.1" upper_limit="2.2"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.1" upper_limit="2.3"/>
                    <measurement group_id="O4" value="1.5" lower_limit="0.5" upper_limit="3.6"/>
                    <measurement group_id="O5" value="1.6" lower_limit="0.5" upper_limit="3.8"/>
                    <measurement group_id="O6" value="1.5" lower_limit="0.5" upper_limit="3.4"/>
                    <measurement group_id="O7" value="0" lower_limit="0" upper_limit="15.4"/>
                    <measurement group_id="O8" value="0" lower_limit="0" upper_limit="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Bleeding Based on BARC Types 1-5</title>
        <description>Number of participants with bleeding based on Bleeding Academic Research Consortium (BARC) Type 1 to 5. BARC bleeding types: 0=No bleeding. 1=Not actionable bleeding. 2=Overt, actionable sign of hemorrhage requiring nonsurgical, medical intervention by a health-care professional, leading to hospitalization or increased level of care, or prompting evaluation. 3a=Overt bleeding plus hemoglobin drop of 3 to &lt; 5 g/dL. 3b=Overt bleeding plus hemoglobin drop ≥5 g/dL; cardiac tamponade; bleeding requiring surgical intervention; bleeding requiring IV vasoactive agents. 3c=Intracranial hemorrhage; intraocular bleed compromising vision. 4=CABG-related bleeding, perioperative intracranial bleeding within 48 hours, reoperation after closure of sternotomy to control bleeding, transfusion of ≥5 U whole blood or packed red blood cells within a 48-hour period, chest tube output more than or equal to 2L within a 24-hour period. 5a=Probable fatal bleeding. 5b=Definite fatal bleeding.</description>
        <time_frame>From first dose to up to 107 days after first dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Milvexian 25 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O3">
            <title>Milvexian 25 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O4">
            <title>Milvexian 50 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O5">
            <title>Milvexian 100 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O6">
            <title>Milvexian 200 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O7">
            <title>Milvexian 50 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O8">
            <title>Milvexian 100 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Bleeding Based on BARC Types 1-5</title>
          <description>Number of participants with bleeding based on Bleeding Academic Research Consortium (BARC) Type 1 to 5. BARC bleeding types: 0=No bleeding. 1=Not actionable bleeding. 2=Overt, actionable sign of hemorrhage requiring nonsurgical, medical intervention by a health-care professional, leading to hospitalization or increased level of care, or prompting evaluation. 3a=Overt bleeding plus hemoglobin drop of 3 to &lt; 5 g/dL. 3b=Overt bleeding plus hemoglobin drop ≥5 g/dL; cardiac tamponade; bleeding requiring surgical intervention; bleeding requiring IV vasoactive agents. 3c=Intracranial hemorrhage; intraocular bleed compromising vision. 4=CABG-related bleeding, perioperative intracranial bleeding within 48 hours, reoperation after closure of sternotomy to control bleeding, transfusion of ≥5 U whole blood or packed red blood cells within a 48-hour period, chest tube output more than or equal to 2L within a 24-hour period. 5a=Probable fatal bleeding. 5b=Definite fatal bleeding.</description>
          <population>All treated participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="682"/>
                <count group_id="O2" value="325"/>
                <count group_id="O3" value="313"/>
                <count group_id="O4" value="325"/>
                <count group_id="O5" value="306"/>
                <count group_id="O6" value="344"/>
                <count group_id="O7" value="22"/>
                <count group_id="O8" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Type 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="25"/>
                    <measurement group_id="O6" value="22"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 3A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 3B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 3C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 5A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 5B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Bleeding Based on ISTH-Defined Criteria</title>
        <description>Number of participants with bleeding based on International Society on Thrombosis and Hemostasis (ISTH). ISTH Bleeding Types: 1) Fatal bleeding and/or 2) Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome and/or 3) Bleeding causing a fall in hemoglobin level of ≥2 g/dL, or leading to transfusion of ≥2 units of whole blood or red cells.</description>
        <time_frame>From first dose to up to 107 days after first dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Milvexian 25 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O3">
            <title>Milvexian 25 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O4">
            <title>Milvexian 50 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O5">
            <title>Milvexian 100 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O6">
            <title>Milvexian 200 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O7">
            <title>Milvexian 50 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O8">
            <title>Milvexian 100 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Bleeding Based on ISTH-Defined Criteria</title>
          <description>Number of participants with bleeding based on International Society on Thrombosis and Hemostasis (ISTH). ISTH Bleeding Types: 1) Fatal bleeding and/or 2) Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome and/or 3) Bleeding causing a fall in hemoglobin level of ≥2 g/dL, or leading to transfusion of ≥2 units of whole blood or red cells.</description>
          <population>All treated participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="682"/>
                <count group_id="O2" value="325"/>
                <count group_id="O3" value="313"/>
                <count group_id="O4" value="325"/>
                <count group_id="O5" value="306"/>
                <count group_id="O6" value="344"/>
                <count group_id="O7" value="22"/>
                <count group_id="O8" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Major</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically Relevant Non-Major (CRNM)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major or CRNM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="13"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor Bleed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="26"/>
                    <measurement group_id="O6" value="22"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Bleeding Based on PLATO-Defined Criteria</title>
        <description>Number of participants with bleeding based on Platelet Inhibition and Patient Outcomes (PLATO) defined criteria. PLATO bleeding definitions:&#xD;
Major Life-threatening: Fatal, Intracranial, Intrapericardial with cardiac tamponade, Resulting in hypovolemic shock or severe hypotension that requires pressors or surgery, Clinically overt or apparent bleeding associated with decrease in hemoglobin &gt;5 g/dL, Requiring transfusion of ≥4 U whole blood or packed red blood cells (PRBCs)&#xD;
Other Major: Significantly disabling (eg, intraocular with permanent vision loss), Associated drop in hemoglobin of 3 to 5 g/dL, Requiring transfusion of 2 to 3 U whole blood or PRBCs&#xD;
Any Major: Any one of the above criteria&#xD;
Minor: Bleeding that does not meet criteria for PLATO Major bleeding, and requiring medical intervention</description>
        <time_frame>From first dose to up to 107 days after first dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Milvexian 25 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O3">
            <title>Milvexian 25 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O4">
            <title>Milvexian 50 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O5">
            <title>Milvexian 100 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O6">
            <title>Milvexian 200 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O7">
            <title>Milvexian 50 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O8">
            <title>Milvexian 100 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Bleeding Based on PLATO-Defined Criteria</title>
          <description>Number of participants with bleeding based on Platelet Inhibition and Patient Outcomes (PLATO) defined criteria. PLATO bleeding definitions:&#xD;
Major Life-threatening: Fatal, Intracranial, Intrapericardial with cardiac tamponade, Resulting in hypovolemic shock or severe hypotension that requires pressors or surgery, Clinically overt or apparent bleeding associated with decrease in hemoglobin &gt;5 g/dL, Requiring transfusion of ≥4 U whole blood or packed red blood cells (PRBCs)&#xD;
Other Major: Significantly disabling (eg, intraocular with permanent vision loss), Associated drop in hemoglobin of 3 to 5 g/dL, Requiring transfusion of 2 to 3 U whole blood or PRBCs&#xD;
Any Major: Any one of the above criteria&#xD;
Minor: Bleeding that does not meet criteria for PLATO Major bleeding, and requiring medical intervention</description>
          <population>All treated participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="682"/>
                <count group_id="O2" value="325"/>
                <count group_id="O3" value="313"/>
                <count group_id="O4" value="325"/>
                <count group_id="O5" value="306"/>
                <count group_id="O6" value="344"/>
                <count group_id="O7" value="22"/>
                <count group_id="O8" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MAJOR LIFE-THREATENING</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OTHER MAJOR BLEEDING</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANY MAJOR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MINOR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MINIMAL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="26"/>
                    <measurement group_id="O6" value="21"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Descriptive Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90</title>
        <description>Descriptive Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90.</description>
        <time_frame>From randomization to up to 90 days after randomization</time_frame>
        <population>All randomized participants who experienced a new ischemic stroke by day 90, or an evaluable day 90 MRI regardless of when the MRI was collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Milvexian 25 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O3">
            <title>Milvexian 25 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O4">
            <title>Milvexian 50 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O5">
            <title>Milvexian 100 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O6">
            <title>Milvexian 200 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O7">
            <title>Milvexian 50 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O8">
            <title>Milvexian 100 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Descriptive Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90</title>
          <description>Descriptive Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90.</description>
          <population>All randomized participants who experienced a new ischemic stroke by day 90, or an evaluable day 90 MRI regardless of when the MRI was collected.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="625"/>
                <count group_id="O2" value="308"/>
                <count group_id="O3" value="287"/>
                <count group_id="O4" value="306"/>
                <count group_id="O5" value="277"/>
                <count group_id="O6" value="317"/>
                <count group_id="O7" value="21"/>
                <count group_id="O8" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6"/>
                    <measurement group_id="O2" value="16.2"/>
                    <measurement group_id="O3" value="18.5"/>
                    <measurement group_id="O4" value="14.1"/>
                    <measurement group_id="O5" value="14.8"/>
                    <measurement group_id="O6" value="16.4"/>
                    <measurement group_id="O7" value="19.0"/>
                    <measurement group_id="O8" value="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite of Percent of Participants With New Ischemic Stroke, MI and All Cause Death</title>
        <description>Composite of percent of participants of new ischemic stroke, (Myocardial Infarction) MI and all cause death.</description>
        <time_frame>From randomization to up to 90 days after randomization</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Milvexian 25 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O3">
            <title>Milvexian 25 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O4">
            <title>Milvexian 50 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O5">
            <title>Milvexian 100 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O6">
            <title>Milvexian 200 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O7">
            <title>Milvexian 50 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O8">
            <title>Milvexian 100 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Composite of Percent of Participants With New Ischemic Stroke, MI and All Cause Death</title>
          <description>Composite of percent of participants of new ischemic stroke, (Myocardial Infarction) MI and all cause death.</description>
          <population>All randomized participants</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="691"/>
                <count group_id="O2" value="328"/>
                <count group_id="O3" value="318"/>
                <count group_id="O4" value="328"/>
                <count group_id="O5" value="310"/>
                <count group_id="O6" value="351"/>
                <count group_id="O7" value="22"/>
                <count group_id="O8" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" lower_limit="4.3" upper_limit="7.9"/>
                    <measurement group_id="O2" value="5.2" lower_limit="2.8" upper_limit="7.6"/>
                    <measurement group_id="O3" value="4.7" lower_limit="2.4" upper_limit="7.0"/>
                    <measurement group_id="O4" value="4.9" lower_limit="2.5" upper_limit="7.2"/>
                    <measurement group_id="O5" value="5.2" lower_limit="2.7" upper_limit="7.6"/>
                    <measurement group_id="O6" value="9.4" lower_limit="6.3" upper_limit="12.5"/>
                    <measurement group_id="O7" value="18.2" lower_limit="2.1" upper_limit="34.3"/>
                    <measurement group_id="O8" value="5.6" lower_limit="0" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>National Institutes of Health Stroke Scale (NIHSS)</title>
        <description>The NIHSS is an 11-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. The score for each ability is a number between 0 and 4, 0 being normal functioning and 4 being completely impaired. The patient's NIHSS score is calculated by adding the number for each element of the scale; 42 is the highest score possible. In the NIHSS, the higher the score, the more impaired a stroke participant is.</description>
        <time_frame>At baseline, on Days 21 and 90, and at the time of a new stroke event</time_frame>
        <population>All randomized participants with a complete NIHSS assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Milvexian 25 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O3">
            <title>Milvexian 25 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O4">
            <title>Milvexian 50 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O5">
            <title>Milvexian 100 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O6">
            <title>Milvexian 200 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O7">
            <title>Milvexian 50 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O8">
            <title>Milvexian 100 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
        </group_list>
        <measure>
          <title>National Institutes of Health Stroke Scale (NIHSS)</title>
          <description>The NIHSS is an 11-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. The score for each ability is a number between 0 and 4, 0 being normal functioning and 4 being completely impaired. The patient's NIHSS score is calculated by adding the number for each element of the scale; 42 is the highest score possible. In the NIHSS, the higher the score, the more impaired a stroke participant is.</description>
          <population>All randomized participants with a complete NIHSS assessment</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="684"/>
                <count group_id="O2" value="324"/>
                <count group_id="O3" value="311"/>
                <count group_id="O4" value="326"/>
                <count group_id="O5" value="305"/>
                <count group_id="O6" value="348"/>
                <count group_id="O7" value="22"/>
                <count group_id="O8" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="684"/>
                    <count group_id="O2" value="324"/>
                    <count group_id="O3" value="311"/>
                    <count group_id="O4" value="326"/>
                    <count group_id="O5" value="305"/>
                    <count group_id="O6" value="348"/>
                    <count group_id="O7" value="22"/>
                    <count group_id="O8" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="1.87"/>
                    <measurement group_id="O2" value="1.7" spread="1.68"/>
                    <measurement group_id="O3" value="1.6" spread="1.73"/>
                    <measurement group_id="O4" value="1.6" spread="1.79"/>
                    <measurement group_id="O5" value="1.8" spread="1.81"/>
                    <measurement group_id="O6" value="1.6" spread="1.79"/>
                    <measurement group_id="O7" value="1.1" spread="1.44"/>
                    <measurement group_id="O8" value="2.0" spread="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="624"/>
                    <count group_id="O2" value="294"/>
                    <count group_id="O3" value="280"/>
                    <count group_id="O4" value="301"/>
                    <count group_id="O5" value="271"/>
                    <count group_id="O6" value="314"/>
                    <count group_id="O7" value="18"/>
                    <count group_id="O8" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="2.11"/>
                    <measurement group_id="O2" value="0.8" spread="1.35"/>
                    <measurement group_id="O3" value="0.8" spread="1.43"/>
                    <measurement group_id="O4" value="0.8" spread="1.58"/>
                    <measurement group_id="O5" value="0.8" spread="1.48"/>
                    <measurement group_id="O6" value="0.9" spread="1.88"/>
                    <measurement group_id="O7" value="0.8" spread="1.90"/>
                    <measurement group_id="O8" value="0.9" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="552"/>
                    <count group_id="O2" value="263"/>
                    <count group_id="O3" value="251"/>
                    <count group_id="O4" value="259"/>
                    <count group_id="O5" value="238"/>
                    <count group_id="O6" value="256"/>
                    <count group_id="O7" value="20"/>
                    <count group_id="O8" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.40"/>
                    <measurement group_id="O2" value="0.6" spread="1.06"/>
                    <measurement group_id="O3" value="0.6" spread="1.51"/>
                    <measurement group_id="O4" value="0.6" spread="1.14"/>
                    <measurement group_id="O5" value="0.6" spread="1.32"/>
                    <measurement group_id="O6" value="0.6" spread="1.29"/>
                    <measurement group_id="O7" value="0.3" spread="0.72"/>
                    <measurement group_id="O8" value="0.6" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First recurrent stroke</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="20"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="5.01"/>
                    <measurement group_id="O2" value="4.6" spread="6.79"/>
                    <measurement group_id="O3" value="5.4" spread="3.17"/>
                    <measurement group_id="O4" value="4.6" spread="4.30"/>
                    <measurement group_id="O5" value="7.1" spread="4.68"/>
                    <measurement group_id="O6" value="4.4" spread="4.60"/>
                    <measurement group_id="O7" value="5.3" spread="3.06"/>
                    <measurement group_id="O8" value="1.0" spread="NA">Insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Rankin Scale (mRS)</title>
        <description>The Modified Rankin Score (mRS) is a 6-point disability scale with possible scores ranging from 0 to 6.&#xD;
0 = No symptoms at all&#xD;
= No significant disability despite symptoms; able to carry out all usual duties and activities&#xD;
= Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance&#xD;
= Moderate disability; requiring some help, but able to walk without assistance&#xD;
= Moderately severe disability; unable to walk and attend to bodily needs without assistance&#xD;
= Severe disability; bedridden, incontinent and requiring constant nursing care and attention&#xD;
= Dead</description>
        <time_frame>At baseline, on Days 21 and 90, and at the time of a new stroke event</time_frame>
        <population>All randomized participants with a complete mRS assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Milvexian 25 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O3">
            <title>Milvexian 25 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O4">
            <title>Milvexian 50 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O5">
            <title>Milvexian 100 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O6">
            <title>Milvexian 200 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O7">
            <title>Milvexian 50 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O8">
            <title>Milvexian 100 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Rankin Scale (mRS)</title>
          <description>The Modified Rankin Score (mRS) is a 6-point disability scale with possible scores ranging from 0 to 6.&#xD;
0 = No symptoms at all&#xD;
= No significant disability despite symptoms; able to carry out all usual duties and activities&#xD;
= Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance&#xD;
= Moderate disability; requiring some help, but able to walk without assistance&#xD;
= Moderately severe disability; unable to walk and attend to bodily needs without assistance&#xD;
= Severe disability; bedridden, incontinent and requiring constant nursing care and attention&#xD;
= Dead</description>
          <population>All randomized participants with a complete mRS assessment</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="688"/>
                <count group_id="O2" value="326"/>
                <count group_id="O3" value="314"/>
                <count group_id="O4" value="328"/>
                <count group_id="O5" value="309"/>
                <count group_id="O6" value="349"/>
                <count group_id="O7" value="22"/>
                <count group_id="O8" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="688"/>
                    <count group_id="O2" value="326"/>
                    <count group_id="O3" value="314"/>
                    <count group_id="O4" value="328"/>
                    <count group_id="O5" value="309"/>
                    <count group_id="O6" value="349"/>
                    <count group_id="O7" value="22"/>
                    <count group_id="O8" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.87"/>
                    <measurement group_id="O2" value="0.6" spread="0.95"/>
                    <measurement group_id="O3" value="0.6" spread="0.96"/>
                    <measurement group_id="O4" value="0.5" spread="0.86"/>
                    <measurement group_id="O5" value="0.5" spread="0.89"/>
                    <measurement group_id="O6" value="0.6" spread="0.95"/>
                    <measurement group_id="O7" value="0.2" spread="0.53"/>
                    <measurement group_id="O8" value="0.7" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="630"/>
                    <count group_id="O2" value="301"/>
                    <count group_id="O3" value="287"/>
                    <count group_id="O4" value="306"/>
                    <count group_id="O5" value="279"/>
                    <count group_id="O6" value="316"/>
                    <count group_id="O7" value="17"/>
                    <count group_id="O8" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="1.18"/>
                    <measurement group_id="O2" value="1.0" spread="1.13"/>
                    <measurement group_id="O3" value="0.9" spread="1.15"/>
                    <measurement group_id="O4" value="0.9" spread="1.15"/>
                    <measurement group_id="O5" value="1.0" spread="1.17"/>
                    <measurement group_id="O6" value="0.9" spread="1.19"/>
                    <measurement group_id="O7" value="0.9" spread="1.27"/>
                    <measurement group_id="O8" value="1.3" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="562"/>
                    <count group_id="O2" value="269"/>
                    <count group_id="O3" value="257"/>
                    <count group_id="O4" value="265"/>
                    <count group_id="O5" value="245"/>
                    <count group_id="O6" value="259"/>
                    <count group_id="O7" value="20"/>
                    <count group_id="O8" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.04"/>
                    <measurement group_id="O2" value="0.8" spread="1.04"/>
                    <measurement group_id="O3" value="0.8" spread="1.07"/>
                    <measurement group_id="O4" value="0.7" spread="1.01"/>
                    <measurement group_id="O5" value="0.7" spread="1.01"/>
                    <measurement group_id="O6" value="0.8" spread="1.05"/>
                    <measurement group_id="O7" value="0.6" spread="1.05"/>
                    <measurement group_id="O8" value="1.0" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First recurrent stroke</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="19"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="1.60"/>
                    <measurement group_id="O2" value="2.7" spread="1.03"/>
                    <measurement group_id="O3" value="2.6" spread="1.35"/>
                    <measurement group_id="O4" value="2.3" spread="1.62"/>
                    <measurement group_id="O5" value="2.9" spread="1.64"/>
                    <measurement group_id="O6" value="1.8" spread="1.72"/>
                    <measurement group_id="O7" value="2.0" spread="0.00"/>
                    <measurement group_id="O8" value="1.0" spread="NA">Insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Montreal Cognitive Assessment (MoCA)</title>
        <description>The Montreal Cognitive Assessment (MoCA) is a survey with a summed score. MoCA score ranges between a lowest score of 0 to a highest score of 30. A score of:&#xD;
≥26 points: indicates normal cognitive function&#xD;
18-25 points: Mild cognitive impairment&#xD;
10-17 points: Moderate cognitive impairment&#xD;
fewer than 10 points: Severe cognitive impairment</description>
        <time_frame>At baseline, on Days 21 and 90, and at the time of a new stroke event</time_frame>
        <population>All randomized participants with a complete MoCA assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Milvexian 25 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O3">
            <title>Milvexian 25 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O4">
            <title>Milvexian 50 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O5">
            <title>Milvexian 100 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O6">
            <title>Milvexian 200 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O7">
            <title>Milvexian 50 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O8">
            <title>Milvexian 100 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Montreal Cognitive Assessment (MoCA)</title>
          <description>The Montreal Cognitive Assessment (MoCA) is a survey with a summed score. MoCA score ranges between a lowest score of 0 to a highest score of 30. A score of:&#xD;
≥26 points: indicates normal cognitive function&#xD;
18-25 points: Mild cognitive impairment&#xD;
10-17 points: Moderate cognitive impairment&#xD;
fewer than 10 points: Severe cognitive impairment</description>
          <population>All randomized participants with a complete MoCA assessment</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="541"/>
                <count group_id="O2" value="257"/>
                <count group_id="O3" value="235"/>
                <count group_id="O4" value="257"/>
                <count group_id="O5" value="235"/>
                <count group_id="O6" value="276"/>
                <count group_id="O7" value="17"/>
                <count group_id="O8" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="541"/>
                    <count group_id="O2" value="257"/>
                    <count group_id="O3" value="235"/>
                    <count group_id="O4" value="257"/>
                    <count group_id="O5" value="235"/>
                    <count group_id="O6" value="276"/>
                    <count group_id="O7" value="17"/>
                    <count group_id="O8" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.3" spread="5.06"/>
                    <measurement group_id="O2" value="21.6" spread="5.59"/>
                    <measurement group_id="O3" value="22.0" spread="5.18"/>
                    <measurement group_id="O4" value="22.5" spread="4.82"/>
                    <measurement group_id="O5" value="22.4" spread="5.04"/>
                    <measurement group_id="O6" value="22.1" spread="5.31"/>
                    <measurement group_id="O7" value="24.4" spread="3.84"/>
                    <measurement group_id="O8" value="22.0" spread="4.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="492"/>
                    <count group_id="O2" value="231"/>
                    <count group_id="O3" value="206"/>
                    <count group_id="O4" value="236"/>
                    <count group_id="O5" value="211"/>
                    <count group_id="O6" value="251"/>
                    <count group_id="O7" value="15"/>
                    <count group_id="O8" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" spread="4.77"/>
                    <measurement group_id="O2" value="23.9" spread="5.01"/>
                    <measurement group_id="O3" value="24.0" spread="4.70"/>
                    <measurement group_id="O4" value="24.3" spread="4.57"/>
                    <measurement group_id="O5" value="23.6" spread="4.48"/>
                    <measurement group_id="O6" value="24.0" spread="4.96"/>
                    <measurement group_id="O7" value="26.4" spread="2.61"/>
                    <measurement group_id="O8" value="24.1" spread="4.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="435"/>
                    <count group_id="O2" value="208"/>
                    <count group_id="O3" value="183"/>
                    <count group_id="O4" value="209"/>
                    <count group_id="O5" value="180"/>
                    <count group_id="O6" value="210"/>
                    <count group_id="O7" value="15"/>
                    <count group_id="O8" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6" spread="4.54"/>
                    <measurement group_id="O2" value="24.0" spread="4.69"/>
                    <measurement group_id="O3" value="24.2" spread="4.80"/>
                    <measurement group_id="O4" value="24.4" spread="4.48"/>
                    <measurement group_id="O5" value="24.5" spread="4.36"/>
                    <measurement group_id="O6" value="24.2" spread="5.05"/>
                    <measurement group_id="O7" value="25.0" spread="4.72"/>
                    <measurement group_id="O8" value="26.4" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First recurrent stroke</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2" spread="6.63"/>
                    <measurement group_id="O2" value="17.3" spread="6.11"/>
                    <measurement group_id="O3" value="25.3" spread="2.31"/>
                    <measurement group_id="O4" value="19.0" spread="8.49"/>
                    <measurement group_id="O5" value="3.0" spread="NA">Insufficient number of participants with events</measurement>
                    <measurement group_id="O6" value="23.1" spread="7.08"/>
                    <measurement group_id="O7" value="11.0" spread="NA">Insufficient number of participants with events</measurement>
                    <measurement group_id="O8" value="22.0" spread="NA">Insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Digit Symbol Substitution Test (DSST)</title>
        <description>The Descriptive Summary of the Digit Symbol Substitution Test (DSST) is a scale item, with a lowest score of 0 and highest total score of 135. Higher score indicates better cognitive functioning.</description>
        <time_frame>At baseline, on Days 21 and 90, and at the time of a new stroke event</time_frame>
        <population>All randomized participants with a complete DSST assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Milvexian 25 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O3">
            <title>Milvexian 25 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O4">
            <title>Milvexian 50 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O5">
            <title>Milvexian 100 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O6">
            <title>Milvexian 200 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O7">
            <title>Milvexian 50 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O8">
            <title>Milvexian 100 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Digit Symbol Substitution Test (DSST)</title>
          <description>The Descriptive Summary of the Digit Symbol Substitution Test (DSST) is a scale item, with a lowest score of 0 and highest total score of 135. Higher score indicates better cognitive functioning.</description>
          <population>All randomized participants with a complete DSST assessment</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="493"/>
                <count group_id="O2" value="238"/>
                <count group_id="O3" value="209"/>
                <count group_id="O4" value="234"/>
                <count group_id="O5" value="220"/>
                <count group_id="O6" value="257"/>
                <count group_id="O7" value="17"/>
                <count group_id="O8" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="493"/>
                    <count group_id="O2" value="238"/>
                    <count group_id="O3" value="209"/>
                    <count group_id="O4" value="234"/>
                    <count group_id="O5" value="220"/>
                    <count group_id="O6" value="257"/>
                    <count group_id="O7" value="17"/>
                    <count group_id="O8" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.9" spread="22.36"/>
                    <measurement group_id="O2" value="31.2" spread="18.87"/>
                    <measurement group_id="O3" value="32.9" spread="22.89"/>
                    <measurement group_id="O4" value="37.2" spread="25.67"/>
                    <measurement group_id="O5" value="33.7" spread="21.89"/>
                    <measurement group_id="O6" value="31.7" spread="19.15"/>
                    <measurement group_id="O7" value="47.1" spread="29.34"/>
                    <measurement group_id="O8" value="29.2" spread="18.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="443"/>
                    <count group_id="O2" value="213"/>
                    <count group_id="O3" value="183"/>
                    <count group_id="O4" value="213"/>
                    <count group_id="O5" value="194"/>
                    <count group_id="O6" value="228"/>
                    <count group_id="O7" value="14"/>
                    <count group_id="O8" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.2" spread="22.14"/>
                    <measurement group_id="O2" value="38.9" spread="19.27"/>
                    <measurement group_id="O3" value="40.2" spread="21.60"/>
                    <measurement group_id="O4" value="45.1" spread="25.77"/>
                    <measurement group_id="O5" value="41.2" spread="22.87"/>
                    <measurement group_id="O6" value="39.1" spread="21.35"/>
                    <measurement group_id="O7" value="54.6" spread="32.73"/>
                    <measurement group_id="O8" value="37.1" spread="20.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="394"/>
                    <count group_id="O2" value="191"/>
                    <count group_id="O3" value="160"/>
                    <count group_id="O4" value="186"/>
                    <count group_id="O5" value="166"/>
                    <count group_id="O6" value="192"/>
                    <count group_id="O7" value="15"/>
                    <count group_id="O8" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.8" spread="21.18"/>
                    <measurement group_id="O2" value="41.7" spread="21.66"/>
                    <measurement group_id="O3" value="41.3" spread="20.29"/>
                    <measurement group_id="O4" value="45.2" spread="21.86"/>
                    <measurement group_id="O5" value="45.5" spread="23.44"/>
                    <measurement group_id="O6" value="41.4" spread="21.97"/>
                    <measurement group_id="O7" value="47.5" spread="27.48"/>
                    <measurement group_id="O8" value="40.7" spread="17.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First recurrent stroke</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3" spread="13.56"/>
                    <measurement group_id="O2" value="28.0" spread="20.95"/>
                    <measurement group_id="O3" value="42.0" spread="4.36"/>
                    <measurement group_id="O4" value="40.5" spread="2.12"/>
                    <measurement group_id="O5" value="23.0" spread="NA">Insufficient number of participants with events</measurement>
                    <measurement group_id="O6" value="27.5" spread="16.96"/>
                    <measurement group_id="O7" value="9.0" spread="NA">Insufficient number of participants with events</measurement>
                    <measurement group_id="O8" value="47.0" spread="NA">Insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AEs)</title>
        <description>AE: include all non-serious adverse events with onset on or after first dose date and within 2 days after the last dose of study treatment.</description>
        <time_frame>From first dose to 2 days after last dose of study therapy (up to approximately 107 days)</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Milvexian 25 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O3">
            <title>Milvexian 25 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O4">
            <title>Milvexian 50 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O5">
            <title>Milvexian 100 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O6">
            <title>Milvexian 200 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O7">
            <title>Milvexian 50 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O8">
            <title>Milvexian 100 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs)</title>
          <description>AE: include all non-serious adverse events with onset on or after first dose date and within 2 days after the last dose of study treatment.</description>
          <population>All treated participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="682"/>
                <count group_id="O2" value="325"/>
                <count group_id="O3" value="313"/>
                <count group_id="O4" value="325"/>
                <count group_id="O5" value="306"/>
                <count group_id="O6" value="344"/>
                <count group_id="O7" value="22"/>
                <count group_id="O8" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="399"/>
                    <measurement group_id="O2" value="190"/>
                    <measurement group_id="O3" value="186"/>
                    <measurement group_id="O4" value="192"/>
                    <measurement group_id="O5" value="193"/>
                    <measurement group_id="O6" value="211"/>
                    <measurement group_id="O7" value="11"/>
                    <measurement group_id="O8" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Vital Sign Abnormalities</title>
        <description>Number of participants with clinically significant vital sign abnormalities. Vital signs included heart rate and diastolic and systolic blood pressure.</description>
        <time_frame>From first dose to up to 90 days after first dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Milvexian 25 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O3">
            <title>Milvexian 25 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O4">
            <title>Milvexian 50 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O5">
            <title>Milvexian 100 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O6">
            <title>Milvexian 200 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O7">
            <title>Milvexian 50 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O8">
            <title>Milvexian 100 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Vital Sign Abnormalities</title>
          <description>Number of participants with clinically significant vital sign abnormalities. Vital signs included heart rate and diastolic and systolic blood pressure.</description>
          <population>All treated participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="682"/>
                <count group_id="O2" value="325"/>
                <count group_id="O3" value="313"/>
                <count group_id="O4" value="325"/>
                <count group_id="O5" value="306"/>
                <count group_id="O6" value="344"/>
                <count group_id="O7" value="22"/>
                <count group_id="O8" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Physical Examination Abnormalities</title>
        <description>Number of participants with clinically significant physical examination abnormalities.</description>
        <time_frame>From first dose to up to 90 days after first dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Milvexian 25 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O3">
            <title>Milvexian 25 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O4">
            <title>Milvexian 50 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O5">
            <title>Milvexian 100 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O6">
            <title>Milvexian 200 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O7">
            <title>Milvexian 50 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O8">
            <title>Milvexian 100 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Physical Examination Abnormalities</title>
          <description>Number of participants with clinically significant physical examination abnormalities.</description>
          <population>All treated participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="682"/>
                <count group_id="O2" value="325"/>
                <count group_id="O3" value="313"/>
                <count group_id="O4" value="325"/>
                <count group_id="O5" value="306"/>
                <count group_id="O6" value="344"/>
                <count group_id="O7" value="22"/>
                <count group_id="O8" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities</title>
        <description>Number of participants with clinically significant ECG abnormalities.</description>
        <time_frame>From first dose to up to 90 days after first dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Milvexian 25 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O3">
            <title>Milvexian 25 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O4">
            <title>Milvexian 50 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O5">
            <title>Milvexian 100 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O6">
            <title>Milvexian 200 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O7">
            <title>Milvexian 50 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O8">
            <title>Milvexian 100 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities</title>
          <description>Number of participants with clinically significant ECG abnormalities.</description>
          <population>All treated participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="682"/>
                <count group_id="O2" value="325"/>
                <count group_id="O3" value="313"/>
                <count group_id="O4" value="325"/>
                <count group_id="O5" value="306"/>
                <count group_id="O6" value="344"/>
                <count group_id="O7" value="22"/>
                <count group_id="O8" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Laboratory Abnormalities - Liver</title>
        <description>The number of treated participants who experienced a laboratory abnormality of the liver during the course of the study.&#xD;
Aspartate aminotransferase (AST) Alanine aminotransferase (ALT) Upper Limit of Normal (ULN) Results reported in International System of Units (SI)</description>
        <time_frame>From first dose to up to approximately 38 months</time_frame>
        <population>All treated participants with at least one clinically significant liver laboratory abnormality</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Milvexian 25 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O3">
            <title>Milvexian 25 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O4">
            <title>Milvexian 50 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O5">
            <title>Milvexian 100 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O6">
            <title>Milvexian 200 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O7">
            <title>Milvexian 50 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O8">
            <title>Milvexian 100 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Laboratory Abnormalities - Liver</title>
          <description>The number of treated participants who experienced a laboratory abnormality of the liver during the course of the study.&#xD;
Aspartate aminotransferase (AST) Alanine aminotransferase (ALT) Upper Limit of Normal (ULN) Results reported in International System of Units (SI)</description>
          <population>All treated participants with at least one clinically significant liver laboratory abnormality</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="642"/>
                <count group_id="O2" value="303"/>
                <count group_id="O3" value="280"/>
                <count group_id="O4" value="306"/>
                <count group_id="O5" value="281"/>
                <count group_id="O6" value="324"/>
                <count group_id="O7" value="21"/>
                <count group_id="O8" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT &gt; 3x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="642"/>
                    <count group_id="O2" value="303"/>
                    <count group_id="O3" value="280"/>
                    <count group_id="O4" value="306"/>
                    <count group_id="O5" value="280"/>
                    <count group_id="O6" value="324"/>
                    <count group_id="O7" value="20"/>
                    <count group_id="O8" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT &gt; 5x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="642"/>
                    <count group_id="O2" value="303"/>
                    <count group_id="O3" value="280"/>
                    <count group_id="O4" value="306"/>
                    <count group_id="O5" value="280"/>
                    <count group_id="O6" value="324"/>
                    <count group_id="O7" value="20"/>
                    <count group_id="O8" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT &gt; 10x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="642"/>
                    <count group_id="O2" value="303"/>
                    <count group_id="O3" value="280"/>
                    <count group_id="O4" value="306"/>
                    <count group_id="O5" value="280"/>
                    <count group_id="O6" value="324"/>
                    <count group_id="O7" value="20"/>
                    <count group_id="O8" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT &gt; 20x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="642"/>
                    <count group_id="O2" value="303"/>
                    <count group_id="O3" value="280"/>
                    <count group_id="O4" value="306"/>
                    <count group_id="O5" value="280"/>
                    <count group_id="O6" value="324"/>
                    <count group_id="O7" value="20"/>
                    <count group_id="O8" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST &gt; 3x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="641"/>
                    <count group_id="O2" value="302"/>
                    <count group_id="O3" value="280"/>
                    <count group_id="O4" value="304"/>
                    <count group_id="O5" value="281"/>
                    <count group_id="O6" value="323"/>
                    <count group_id="O7" value="21"/>
                    <count group_id="O8" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST &gt; 5x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="641"/>
                    <count group_id="O2" value="302"/>
                    <count group_id="O3" value="280"/>
                    <count group_id="O4" value="304"/>
                    <count group_id="O5" value="281"/>
                    <count group_id="O6" value="323"/>
                    <count group_id="O7" value="21"/>
                    <count group_id="O8" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST &gt; 10x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="641"/>
                    <count group_id="O2" value="302"/>
                    <count group_id="O3" value="280"/>
                    <count group_id="O4" value="304"/>
                    <count group_id="O5" value="281"/>
                    <count group_id="O6" value="323"/>
                    <count group_id="O7" value="21"/>
                    <count group_id="O8" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST &gt; 20x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="641"/>
                    <count group_id="O2" value="302"/>
                    <count group_id="O3" value="280"/>
                    <count group_id="O4" value="304"/>
                    <count group_id="O5" value="281"/>
                    <count group_id="O6" value="323"/>
                    <count group_id="O7" value="21"/>
                    <count group_id="O8" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP &gt; 2x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="640"/>
                    <count group_id="O2" value="300"/>
                    <count group_id="O3" value="276"/>
                    <count group_id="O4" value="305"/>
                    <count group_id="O5" value="279"/>
                    <count group_id="O6" value="319"/>
                    <count group_id="O7" value="20"/>
                    <count group_id="O8" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin &gt; 1.5x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="639"/>
                    <count group_id="O2" value="302"/>
                    <count group_id="O3" value="277"/>
                    <count group_id="O4" value="304"/>
                    <count group_id="O5" value="279"/>
                    <count group_id="O6" value="318"/>
                    <count group_id="O7" value="20"/>
                    <count group_id="O8" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin &gt; 2x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="639"/>
                    <count group_id="O2" value="302"/>
                    <count group_id="O3" value="277"/>
                    <count group_id="O4" value="304"/>
                    <count group_id="O5" value="279"/>
                    <count group_id="O6" value="318"/>
                    <count group_id="O7" value="20"/>
                    <count group_id="O8" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concurrent ALT/AST Elevation &gt; 3x ULN with total bilirubin &gt;2x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="639"/>
                    <count group_id="O2" value="302"/>
                    <count group_id="O3" value="277"/>
                    <count group_id="O4" value="304"/>
                    <count group_id="O5" value="279"/>
                    <count group_id="O6" value="318"/>
                    <count group_id="O7" value="20"/>
                    <count group_id="O8" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in aPTT Activity</title>
        <description>Percent change from baseline in activated partial thromboplastin time (aPTT) activity via exposure response.</description>
        <time_frame>Baseline and day 90</time_frame>
        <population>All participants with at least one aPTT pharmacodynamic endpoint assessed after first dose</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Milvexian 25 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O3">
            <title>Milvexian 25 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O4">
            <title>Milvexian 50 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O5">
            <title>Milvexian 100 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O6">
            <title>Milvexian 200 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O7">
            <title>Milvexian 50 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O8">
            <title>Milvexian 100 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in aPTT Activity</title>
          <description>Percent change from baseline in activated partial thromboplastin time (aPTT) activity via exposure response.</description>
          <population>All participants with at least one aPTT pharmacodynamic endpoint assessed after first dose</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="251"/>
                <count group_id="O3" value="226"/>
                <count group_id="O4" value="241"/>
                <count group_id="O5" value="214"/>
                <count group_id="O6" value="232"/>
                <count group_id="O7" value="14"/>
                <count group_id="O8" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.47" spread="0.768"/>
                    <measurement group_id="O2" value="38.72" spread="2.264"/>
                    <measurement group_id="O3" value="58.30" spread="3.195"/>
                    <measurement group_id="O4" value="97.32" spread="3.601"/>
                    <measurement group_id="O5" value="140.76" spread="5.154"/>
                    <measurement group_id="O6" value="193.64" spread="7.041"/>
                    <measurement group_id="O7" value="48.48" spread="11.243"/>
                    <measurement group_id="O8" value="118.06" spread="13.840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Factor XI Clotting Activity</title>
        <description>Percent change from baseline in factor XI clotting activity via exposure response.</description>
        <time_frame>Baseline and day 90</time_frame>
        <population>All participants with at least one factor XI clotting pharmacodynamic endpoint assessed after first dose</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Milvexian 25 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O3">
            <title>Milvexian 25 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O4">
            <title>Milvexian 50 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O5">
            <title>Milvexian 100 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O6">
            <title>Milvexian 200 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O7">
            <title>Milvexian 50 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O8">
            <title>Milvexian 100 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Factor XI Clotting Activity</title>
          <description>Percent change from baseline in factor XI clotting activity via exposure response.</description>
          <population>All participants with at least one factor XI clotting pharmacodynamic endpoint assessed after first dose</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="251"/>
                <count group_id="O3" value="223"/>
                <count group_id="O4" value="228"/>
                <count group_id="O5" value="216"/>
                <count group_id="O6" value="236"/>
                <count group_id="O7" value="15"/>
                <count group_id="O8" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.48" spread="3.455"/>
                    <measurement group_id="O2" value="-8.88" spread="1.280"/>
                    <measurement group_id="O3" value="-17.67" spread="1.900"/>
                    <measurement group_id="O4" value="-37.20" spread="1.655"/>
                    <measurement group_id="O5" value="-61.52" spread="1.869"/>
                    <measurement group_id="O6" value="-70.25" spread="3.043"/>
                    <measurement group_id="O7" value="3.86" spread="13.754"/>
                    <measurement group_id="O8" value="-44.27" spread="6.501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameter - Estimated Clearance (CL)</title>
        <description>Pharmacokinetic Parameter - Estimated Clearance (CL). CL is derived from plasma concentration versus time data. PK parameters were generated using a Population Pharmacokinetics (PPK) model. Summary statistics for these individual predicted PK parameters and exposures were stratified by dose. The PPK model analysis was based on combined PK data collected on days 1, 21, and 90.</description>
        <time_frame>From first dose to up to 90 days after first dose</time_frame>
        <population>All treated participants with at least one post-dose PK sample. Pre-specified for data to be collected only in the 25 mg QD, and BID dose regimens.</population>
        <group_list>
          <group group_id="O1">
            <title>Milvexian 25 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Milvexian 25 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O3">
            <title>Milvexian 50 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O4">
            <title>Milvexian 100 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O5">
            <title>Milvexian 200 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameter - Estimated Clearance (CL)</title>
          <description>Pharmacokinetic Parameter - Estimated Clearance (CL). CL is derived from plasma concentration versus time data. PK parameters were generated using a Population Pharmacokinetics (PPK) model. Summary statistics for these individual predicted PK parameters and exposures were stratified by dose. The PPK model analysis was based on combined PK data collected on days 1, 21, and 90.</description>
          <population>All treated participants with at least one post-dose PK sample. Pre-specified for data to be collected only in the 25 mg QD, and BID dose regimens.</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="307"/>
                <count group_id="O3" value="323"/>
                <count group_id="O4" value="303"/>
                <count group_id="O5" value="341"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.15" spread="34"/>
                    <measurement group_id="O2" value="8.01" spread="34.3"/>
                    <measurement group_id="O3" value="7.54" spread="32.8"/>
                    <measurement group_id="O4" value="7.08" spread="31.3"/>
                    <measurement group_id="O5" value="7.43" spread="32.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameter - Volume of the Central Compartment (VC)</title>
        <description>Pharmacokinetic Parameter - Volume of the Central Compartment (VC). VC is derived from plasma concentration versus time data. PK parameters were generated using a Population Pharmacokinetics (PPK) model. Summary statistics for these individual predicted PK parameters and exposures were stratified by dose. The PPK model analysis was based on combined PK data collected on days 1, 21, and 90.</description>
        <time_frame>From first dose to up to 90 days after first dose</time_frame>
        <population>All treated participants with at least one post-dose PK sample. Pre-specified for data to be collected only in the 25 mg QD, and BID dose regimens.</population>
        <group_list>
          <group group_id="O1">
            <title>Milvexian 25 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Milvexian 25 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O3">
            <title>Milvexian 50 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O4">
            <title>Milvexian 100 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O5">
            <title>Milvexian 200 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameter - Volume of the Central Compartment (VC)</title>
          <description>Pharmacokinetic Parameter - Volume of the Central Compartment (VC). VC is derived from plasma concentration versus time data. PK parameters were generated using a Population Pharmacokinetics (PPK) model. Summary statistics for these individual predicted PK parameters and exposures were stratified by dose. The PPK model analysis was based on combined PK data collected on days 1, 21, and 90.</description>
          <population>All treated participants with at least one post-dose PK sample. Pre-specified for data to be collected only in the 25 mg QD, and BID dose regimens.</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="307"/>
                <count group_id="O3" value="323"/>
                <count group_id="O4" value="303"/>
                <count group_id="O5" value="341"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.9" spread="152"/>
                    <measurement group_id="O2" value="31.4" spread="138"/>
                    <measurement group_id="O3" value="30.9" spread="145"/>
                    <measurement group_id="O4" value="28.9" spread="149"/>
                    <measurement group_id="O5" value="31.6" spread="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Incident Infarcts (New DWI+ or DWI- Lesions) by Participant on Day 90 MRI</title>
        <description>Total volume of diffusion-weighted imaging (DWI) magnetic resonance imaging (MRI) infarcts on the DWI Sequence on day 90 MRI.</description>
        <time_frame>At day 90</time_frame>
        <population>All randomized participants with an evaluable MRI</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Milvexian 25 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O3">
            <title>Milvexian 25 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O4">
            <title>Milvexian 50 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O5">
            <title>Milvexian 100 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O6">
            <title>Milvexian 200 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O7">
            <title>Milvexian 50 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O8">
            <title>Milvexian 100 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Incident Infarcts (New DWI+ or DWI- Lesions) by Participant on Day 90 MRI</title>
          <description>Total volume of diffusion-weighted imaging (DWI) magnetic resonance imaging (MRI) infarcts on the DWI Sequence on day 90 MRI.</description>
          <population>All randomized participants with an evaluable MRI</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="35"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3492" spread="11.40906"/>
                    <measurement group_id="O2" value="0.8976" spread="1.96342"/>
                    <measurement group_id="O3" value="2.9902" spread="8.28993"/>
                    <measurement group_id="O4" value="1.2682" spread="2.72452"/>
                    <measurement group_id="O5" value="1.4727" spread="3.78795"/>
                    <measurement group_id="O6" value="1.2711" spread="4.05035"/>
                    <measurement group_id="O7" value="8.8960" spread="13.85294"/>
                    <measurement group_id="O8" value="1.4503" spread="1.89112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Incident Infarcts (New DWI+ or DWI- Lesions) by Participant on Day 90 MRI</title>
        <description>Number of diffusion-weighted imaging (DWI) magnetic resonance imaging (MRI) infarcts on the DWI Sequence on day 90 MRI.</description>
        <time_frame>At day 90</time_frame>
        <population>All randomized participants with an evaluable MRI</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Milvexian 25 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O3">
            <title>Milvexian 25 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O4">
            <title>Milvexian 50 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O5">
            <title>Milvexian 100 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O6">
            <title>Milvexian 200 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O7">
            <title>Milvexian 50 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O8">
            <title>Milvexian 100 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Incident Infarcts (New DWI+ or DWI- Lesions) by Participant on Day 90 MRI</title>
          <description>Number of diffusion-weighted imaging (DWI) magnetic resonance imaging (MRI) infarcts on the DWI Sequence on day 90 MRI.</description>
          <population>All randomized participants with an evaluable MRI</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="35"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="36"/>
                    <measurement group_id="O5" value="35"/>
                    <measurement group_id="O6" value="35"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="23"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percent of Participants With Ischemic Stroke Events</title>
        <description>Secondary analysis of symptomatic ischemic stroke events. Clinical events are included up to day 90. Wald 95% CI within group. Undetermined stroke is included.</description>
        <time_frame>From randomization to up to 90 days after randomization</time_frame>
        <population>All randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O2">
            <title>Milvexian 25 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O3">
            <title>Milvexian 25 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O4">
            <title>Milvexian 50 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O5">
            <title>Milvexian 100 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O6">
            <title>Milvexian 200 mg BID</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O7">
            <title>Milvexian 50 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
          <group group_id="O8">
            <title>Milvexian 100 mg QD</title>
            <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Ischemic Stroke Events</title>
          <description>Secondary analysis of symptomatic ischemic stroke events. Clinical events are included up to day 90. Wald 95% CI within group. Undetermined stroke is included.</description>
          <population>All randomized participants</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="691"/>
                <count group_id="O2" value="328"/>
                <count group_id="O3" value="318"/>
                <count group_id="O4" value="328"/>
                <count group_id="O5" value="310"/>
                <count group_id="O6" value="351"/>
                <count group_id="O7" value="22"/>
                <count group_id="O8" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ischemic stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="3.8" upper_limit="7.2"/>
                    <measurement group_id="O2" value="4.6" lower_limit="2.3" upper_limit="6.8"/>
                    <measurement group_id="O3" value="3.8" lower_limit="1.7" upper_limit="5.9"/>
                    <measurement group_id="O4" value="4.0" lower_limit="1.9" upper_limit="6.1"/>
                    <measurement group_id="O5" value="3.5" lower_limit="1.5" upper_limit="5.6"/>
                    <measurement group_id="O6" value="7.7" lower_limit="4.9" upper_limit="10.5"/>
                    <measurement group_id="O7" value="13.6" lower_limit="0.0" upper_limit="28.0"/>
                    <measurement group_id="O8" value="5.6" lower_limit="0.0" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Undetermined stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O7" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O8" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Milvexian 25 mg QD over Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Relative Risk (RR)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>1.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Milvexian 25 mg BID over Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Relative Risk (RR)</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.36</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Milvexian 50 mg BID over Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Relative Risk (RR)</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>1.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Milvexian 100 mg BID over Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Relative Risk (RR)</param_type>
            <param_value>0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Milvexian 200 mg BID</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Relative Risk (RR)</param_type>
            <param_value>1.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>2.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Milvexian 50 mg QD over Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Relative Risk (RR)</param_type>
            <param_value>2.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>7.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Milvexian 100 mg QD over Placebo</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Relative Risk (RR)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.15</ci_lower_limit>
            <ci_upper_limit>6.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants were assessed for all-cause mortality from their randomization until their study completion (up to approximately 38 months). SAEs and Other AEs were assessed from first dose to 7 days after last dose of study therapy (up to approximately 112 days).</time_frame>
      <desc>The total number at risk for all-cause mortality represents all participants who were randomized. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants who received at least 1 dose of study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Placebo + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Placebo + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
        </group>
        <group group_id="E2">
          <title>Milvexian 25 mg QD</title>
          <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
        </group>
        <group group_id="E3">
          <title>Milvexian 50 mg QD</title>
          <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
        </group>
        <group group_id="E4">
          <title>Milvexian 100 mg QD</title>
          <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg QD + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg QD + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
        </group>
        <group group_id="E5">
          <title>Milvexian 25 mg BID</title>
          <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 25 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 25 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
        </group>
        <group group_id="E6">
          <title>Milvexian 50 mg BID</title>
          <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 50 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 50 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
        </group>
        <group group_id="E7">
          <title>Milvexian 100 mg BID</title>
          <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 100 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 100 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
        </group>
        <group group_id="E8">
          <title>Milvexian 200 mg BID</title>
          <description>Loading dose of Clopidogrel 300 mg + Aspirin 100 mg followed by Milvexian 200 mg BID + Aspirin 100 mg QD + Clopidogrel 75 mg QD on days 1-21 and Milvexian 200 mg BID + Aspirin 100 mg QD on days 22-90. All administered orally.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 25.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="691"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="328"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="318"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="328"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="310"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="41" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="42" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="54" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Cardiac ventricular thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Nodal rhythm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Prinzmetal angina</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Oesophagitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Peptic ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Small intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Hepatitis fulminant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>COVID-19</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Diverticulitis intestinal perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Infected dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Large intestine infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Wound infection pseudomonas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Cystitis radiation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Post procedural stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Reactive gastropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Intestinal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Sinonasal papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Basilar artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Basilar artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Basilar migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Brain stem stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Carotid artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Cerebral venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Embolic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Focal dyscognitive seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Haemorrhagic transformation stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Lacunar stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Mental impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Neurological symptom</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Peroneal nerve palsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Pseudostroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Sedation complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Stroke in evolution</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Toxic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Vertebral artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Nephropathy toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Toxic epidermal necrolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 25.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="178" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="83" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="92" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="82" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="90" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Increased tendency to bruise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="20" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="24" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="24" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="20" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="19" subjects_at_risk="344"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="682"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="313"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="325"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="344"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bristol-Myers Squibb Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <phone>Please email</phone>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03766581
org study id: CV010-031
nct id: NCT03766581
lead sponsor: 
collaborator: 
has dmc: Yes
is fda regulated drug: Yes
is fda regulated device: No
The purpose of this clinical study is to determine whether the addition of an oral Factor XIa
      Inhibitor to Aspirin and Clopidogrel is more effective than standard therapy in secondary
      stroke prevention.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Prevention
masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
measure: Percent of Participants With Model Based Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90
time frame: From randomization to up to 90 days after randomization
description: Model based assessment estimate for composite event is a customized statistical analysis called MCP-MOD (Multiple Comparison Procedures, MODel) estimation, which is used to check for dose-response relationship. 95% confidence interval (CI) for composite event based on bootstrap (10000 samples).
measure: Percent of Participants With Major Bleeding According to BARC Type 3 and 5
time frame: From first dose to up to 107 days after first dose
description: Percent of participants with major bleeding based on the Bleeding Academic Research Consortium (BARC) Types 3 and 5 definitions. BARC bleeding types:
3a = Overt bleeding plus hemoglobin drop of 3 to < 5 g/dL transfusion with overt bleeding 3b = Overt bleeding plus hemoglobin drop ≥5 g/dL; cardiac tamponade; bleeding requiring surgical intervention for control; bleeding requiring IV vasoactive agents 3c = Intracranial hemorrhage, 5a = Probable fatal bleeding 5b = Definite fatal bleeding
measure: Number of Participants With Bleeding Based on BARC Types 1-5
time frame: From first dose to up to 107 days after first dose
description: Number of participants with bleeding based on Bleeding Academic Research Consortium (BARC) Type 1 to 5. BARC bleeding types: 0=No bleeding. 1=Not actionable bleeding. 2=Overt, actionable sign of hemorrhage requiring nonsurgical, medical intervention by a health-care professional, leading to hospitalization or increased level of care, or prompting evaluation. 3a=Overt bleeding plus hemoglobin drop of 3 to < 5 g/dL. 3b=Overt bleeding plus hemoglobin drop ≥5 g/dL; cardiac tamponade; bleeding requiring surgical intervention; bleeding requiring IV vasoactive agents. 3c=Intracranial hemorrhage; intraocular bleed compromising vision. 4=CABG-related bleeding, perioperative intracranial bleeding within 48 hours, reoperation after closure of sternotomy to control bleeding, transfusion of ≥5 U whole blood or packed red blood cells within a 48-hour period, chest tube output more than or equal to 2L within a 24-hour period. 5a=Probable fatal bleeding. 5b=Definite fatal bleeding.
measure: Number of Participants With Bleeding Based on ISTH-Defined Criteria
time frame: From first dose to up to 107 days after first dose
description: Number of participants with bleeding based on International Society on Thrombosis and Hemostasis (ISTH). ISTH Bleeding Types: 1) Fatal bleeding and/or 2) Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome and/or 3) Bleeding causing a fall in hemoglobin level of ≥2 g/dL, or leading to transfusion of ≥2 units of whole blood or red cells.
measure: Number of Participants With Bleeding Based on PLATO-Defined Criteria
time frame: From first dose to up to 107 days after first dose
description: Number of participants with bleeding based on Platelet Inhibition and Patient Outcomes (PLATO) defined criteria. PLATO bleeding definitions:
Major Life-threatening: Fatal, Intracranial, Intrapericardial with cardiac tamponade, Resulting in hypovolemic shock or severe hypotension that requires pressors or surgery, Clinically overt or apparent bleeding associated with decrease in hemoglobin >5 g/dL, Requiring transfusion of ≥4 U whole blood or packed red blood cells (PRBCs)
Other Major: Significantly disabling (eg, intraocular with permanent vision loss), Associated drop in hemoglobin of 3 to 5 g/dL, Requiring transfusion of 2 to 3 U whole blood or PRBCs
Any Major: Any one of the above criteria
Minor: Bleeding that does not meet criteria for PLATO Major bleeding, and requiring medical intervention
measure: Percent of Participants With Descriptive Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90
time frame: From randomization to up to 90 days after randomization
description: Descriptive Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90.
measure: Composite of Percent of Participants With New Ischemic Stroke, MI and All Cause Death
time frame: From randomization to up to 90 days after randomization
description: Composite of percent of participants of new ischemic stroke, (Myocardial Infarction) MI and all cause death.
measure: National Institutes of Health Stroke Scale (NIHSS)
time frame: At baseline, on Days 21 and 90, and at the time of a new stroke event
description: The NIHSS is an 11-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. The score for each ability is a number between 0 and 4, 0 being normal functioning and 4 being completely impaired. The patient's NIHSS score is calculated by adding the number for each element of the scale; 42 is the highest score possible. In the NIHSS, the higher the score, the more impaired a stroke participant is.
measure: Modified Rankin Scale (mRS)
time frame: At baseline, on Days 21 and 90, and at the time of a new stroke event
description: The Modified Rankin Score (mRS) is a 6-point disability scale with possible scores ranging from 0 to 6.
0 = No symptoms at all
= No significant disability despite symptoms; able to carry out all usual duties and activities
= Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance
= Moderate disability; requiring some help, but able to walk without assistance
= Moderately severe disability; unable to walk and attend to bodily needs without assistance
= Severe disability; bedridden, incontinent and requiring constant nursing care and attention
= Dead
measure: Montreal Cognitive Assessment (MoCA)
time frame: At baseline, on Days 21 and 90, and at the time of a new stroke event
description: The Montreal Cognitive Assessment (MoCA) is a survey with a summed score. MoCA score ranges between a lowest score of 0 to a highest score of 30. A score of:
≥26 points: indicates normal cognitive function
18-25 points: Mild cognitive impairment
10-17 points: Moderate cognitive impairment
fewer than 10 points: Severe cognitive impairment
measure: Digit Symbol Substitution Test (DSST)
time frame: At baseline, on Days 21 and 90, and at the time of a new stroke event
description: The Descriptive Summary of the Digit Symbol Substitution Test (DSST) is a scale item, with a lowest score of 0 and highest total score of 135. Higher score indicates better cognitive functioning.
measure: Number of Participants With Adverse Events (AEs)
time frame: From first dose to 2 days after last dose of study therapy (up to approximately 107 days)
description: AE: include all non-serious adverse events with onset on or after first dose date and within 2 days after the last dose of study treatment.
measure: Number of Participants With Clinically Significant Vital Sign Abnormalities
time frame: From first dose to up to 90 days after first dose
description: Number of participants with clinically significant vital sign abnormalities. Vital signs included heart rate and diastolic and systolic blood pressure.
measure: Number of Participants With Clinically Significant Physical Examination Abnormalities
time frame: From first dose to up to 90 days after first dose
description: Number of participants with clinically significant physical examination abnormalities.
measure: Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities
time frame: From first dose to up to 90 days after first dose
description: Number of participants with clinically significant ECG abnormalities.
measure: Number of Participants With Clinically Significant Laboratory Abnormalities - Liver
time frame: From first dose to up to approximately 38 months
description: The number of treated participants who experienced a laboratory abnormality of the liver during the course of the study.
Aspartate aminotransferase (AST) Alanine aminotransferase (ALT) Upper Limit of Normal (ULN) Results reported in International System of Units (SI)
measure: Percent Change From Baseline in aPTT Activity
time frame: Baseline and day 90
description: Percent change from baseline in activated partial thromboplastin time (aPTT) activity via exposure response.
measure: Percent Change From Baseline in Factor XI Clotting Activity
time frame: Baseline and day 90
description: Percent change from baseline in factor XI clotting activity via exposure response.
measure: Pharmacokinetic Parameter - Estimated Clearance (CL)
time frame: From first dose to up to 90 days after first dose
description: Pharmacokinetic Parameter - Estimated Clearance (CL). CL is derived from plasma concentration versus time data. PK parameters were generated using a Population Pharmacokinetics (PPK) model. Summary statistics for these individual predicted PK parameters and exposures were stratified by dose. The PPK model analysis was based on combined PK data collected on days 1, 21, and 90.
measure: Pharmacokinetic Parameter - Volume of the Central Compartment (VC)
time frame: From first dose to up to 90 days after first dose
description: Pharmacokinetic Parameter - Volume of the Central Compartment (VC). VC is derived from plasma concentration versus time data. PK parameters were generated using a Population Pharmacokinetics (PPK) model. Summary statistics for these individual predicted PK parameters and exposures were stratified by dose. The PPK model analysis was based on combined PK data collected on days 1, 21, and 90.
measure: Volume of Incident Infarcts (New DWI+ or DWI- Lesions) by Participant on Day 90 MRI
time frame: At day 90
description: Total volume of diffusion-weighted imaging (DWI) magnetic resonance imaging (MRI) infarcts on the DWI Sequence on day 90 MRI.
measure: Number of Incident Infarcts (New DWI+ or DWI- Lesions) by Participant on Day 90 MRI
time frame: At day 90
description: Number of diffusion-weighted imaging (DWI) magnetic resonance imaging (MRI) infarcts on the DWI Sequence on day 90 MRI.
measure: Percent of Participants With Ischemic Stroke Events
time frame: From randomization to up to 90 days after randomization
description: Secondary analysis of symptomatic ischemic stroke events. Clinical events are included up to day 90. Wald 95% CI within group. Undetermined stroke is included.
arm group label: BMS-986177 Placebo
arm group type: Placebo Comparator
description: Specified Dose on Specified Days
arm group label: Dose 1: BMS-986177 + Aspirin + Clopidogrel
arm group type: Experimental
description: Specified Dose on Specified Days
arm group label: Dose 2: BMS-986177 + Aspirin + Clopidogrel
arm group type: Experimental
description: Specified Dose on Specified Days
arm group label: Dose 3: BMS-986177 + Aspirin + Clopidogrel
arm group type: Experimental
description: Specified Dose on Specified Days
arm group label: Dose 4: BMS-986177 + Aspirin + Clopidogrel
arm group type: Experimental
description: Specified Dose on Specified Days
arm group label: Dose 5: BMS-986177 + Aspirin + Clopidogrel
arm group type: Experimental
description: Specified Dose on Specified Days
arm group label: Dose 6: BMS-986177 + Aspirin + Clopidogrel
arm group type: Experimental
description: Specified Dose on Specified Days
arm group label: Dose 7: BMS-986177 + Aspirin + Clopidogrel
arm group type: Experimental
description: Specified Dose on Specified Days
intervention type: Drug
intervention name: BMS-986177
description: Oral administration
arm group label: Dose 1: BMS-986177 + Aspirin + Clopidogrel
arm group label: Dose 2: BMS-986177 + Aspirin + Clopidogrel
arm group label: Dose 3: BMS-986177 + Aspirin + Clopidogrel
arm group label: Dose 4: BMS-986177 + Aspirin + Clopidogrel
arm group label: Dose 5: BMS-986177 + Aspirin + Clopidogrel
arm group label: Dose 6: BMS-986177 + Aspirin + Clopidogrel
arm group label: Dose 7: BMS-986177 + Aspirin + Clopidogrel
intervention type: Other
intervention name: Placebo
description: Oral Administration
arm group label: BMS-986177 Placebo
intervention type: Drug
intervention name: Clopidogrel
description: Oral administration
arm group label: BMS-986177 Placebo
arm group label: Dose 1: BMS-986177 + Aspirin + Clopidogrel
arm group label: Dose 2: BMS-986177 + Aspirin + Clopidogrel
arm group label: Dose 3: BMS-986177 + Aspirin + Clopidogrel
arm group label: Dose 4: BMS-986177 + Aspirin + Clopidogrel
arm group label: Dose 5: BMS-986177 + Aspirin + Clopidogrel
arm group label: Dose 6: BMS-986177 + Aspirin + Clopidogrel
arm group label: Dose 7: BMS-986177 + Aspirin + Clopidogrel
intervention type: Drug
intervention name: Aspirin
description: Oral administration
arm group label: BMS-986177 Placebo
arm group label: Dose 1: BMS-986177 + Aspirin + Clopidogrel
arm group label: Dose 2: BMS-986177 + Aspirin + Clopidogrel
arm group label: Dose 3: BMS-986177 + Aspirin + Clopidogrel
arm group label: Dose 4: BMS-986177 + Aspirin + Clopidogrel
arm group label: Dose 5: BMS-986177 + Aspirin + Clopidogrel
arm group label: Dose 6: BMS-986177 + Aspirin + Clopidogrel
arm group label: Dose 7: BMS-986177 + Aspirin + Clopidogrel
criteria: 
gender: All
minimum age: 40 Years
maximum age: N/A
healthy volunteers: No
last name: Bristol-Myers Squibb
role: Study Director
affiliation: Bristol-Myers Squibb
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: Argentina
country: Australia
country: Austria
country: Belgium
country: Brazil
country: Canada
country: Chile
country: China
country: Czechia
country: Denmark
country: Finland
country: France
country: Germany
country: Greece
country: Hong Kong
country: Hungary
country: Israel
country: Italy
country: Japan
country: Korea, Republic of
country: Mexico
country: Norway
country: Poland
country: Russian Federation
country: Spain
country: Sweden
country: Switzerland
country: United Kingdom
country: United States
url: https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
description: BMS Clinical Trial Information
url: https://www.BMSStudyConnect.com
description: BMS Clinical Trial Patient Recruiting
responsible party type: Sponsor
mesh term: Stroke
mesh term: Ischemic Stroke
mesh term: Ischemic Attack, Transient
mesh term: Ischemia
mesh term: Aspirin
mesh term: Clopidogrel
provided document: 
participant flow: 
baseline: 
outcome list: 
reported events: 
certain agreements: 
point of contact: 